Subcutaneous implantable cardioverter defibrillator (ICD)

Systematic Review



Decision Support Document No. 109 ISSN online: 1998-0469

Subcutaneous implantable cardioverter defibrillator (ICD)

Systematic Review



Vienna, March 2018

Project Team

Project leader: Dr.in med. Katharina Hawlik, MSc Authors: Dr. med. Gernot Wagner Dr.in med. Anna Glechner cand. med. Emma Persad cand. med. Theresa Schmalfuß

Project Support

Systematic literature search: Irma Klerings, MA External Review: Ao.Univ.-Prof.Dr. Michael Wolzt, Medizinische Universität Wien Internal Review: Dr.in med. Katharina Hawlik, MSc

Correspondence

Dr.in med. Katharina Hawlik, MSc, Katharina.Hawlik@hta.lbg.ac.at

This report should be referenced as follows:

Wagner G, Glechner A, Persad E. Schmalfuß T. Subcutaneous implantable cardioverter defibrillator (ICD). Decision Support Document No. 109 ;2018. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

Conflict of interest

All authors and the reviewers involved in the production of this report have declared they have no conflicts of interest in relation to the technology assessed according to the Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org).

Disclaimer

The external reviewers did not co-author the scientific report and do not necessarily all agree with its content. Only the LBI-HTA is responsible for errors or omissions that could persist. The final version and the policy recommendations are under the full responsibility of the LBI-HTA.

The HTA Core Model[®], developed within EUnetHTA (www.eunethta.eu), has been utilised when producing the contents and/or structure of this work. The following version of the Model was used: [HTA Core Model Version 4.2]. Use of the HTA Core Model does not guarantee the accuracy, completeness, quality or usefulness of any information or service produced or provided by using the Model.

Commissioned by the Austrian Ministry of Health, this report systematically assessed the intervention described herein as decision support for the inclusion in the catalogue of benefits.

CONTENT INFORMATION

Publisher:

Ludwig Boltzmann Gesellschaft GmbH Nußdorferstr. 64, 6 Stock, A-1090 Wien http://hta.lbg.ac.at/page/imprint

Responsible for content:

Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) Garnisongasse 7/20, A-1090 Vienna http://hta.lbg.ac.at/

Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. Decision support documents of the LBI-HTA are only available to the public via the Internet at http://eprints.hta.lbg.ac.at^w

Decision Support Document No.: 109

ISSN-online: 1998-0469

© 2018 LBI-HTA – All rights reserved

Content

	Executive Summary		
	Zusammenfassung		
1	Scope	13	
	1.1 PICO question		
	1.2 Inclusion criteria	13	
2	Methods		
	2.1 Research questions		
	2.2 Sources		
	2.3 Systematic literature search		
	2.4 Flow chart of study selection		
	2.5 Analysis		
	2.6 Synthesis	18	
3	Description and technical characteristics of technology	19	
4	Health Problem and Current Use	21	
5	Clinical effectiveness		
5	5.1 Outcomes		
	5.2 Included studies		
	5.3 Results	26	
6	Safety		
	6.1 Outcomes		
	6.2 Included Studies	. 29	
	6.3 Results	29	
7	Quality of evidence	33	
8	Discussion	35	
9	Recommendation		
10	References	39	
	Appendix		
	Evidence tables of individual studies included for clinical effectiveness and safety		
	Risk of bias tables and GRADE evidence profile		
	Applicability table		
List of ongoing randomised controlled trials			
	Literature search strategies		
	Search strategy for Pubmed		
	Search strategy for Embase.com (Elsevier)		
	Search strategy for Cochrane Library (Wiley)		
	Search strategy for CRD Databases	.56	

List of Figures

Figure 2-1:	Flow chart of study selection	(PRISMA Flow Diagram)17	7
-------------	-------------------------------	-------------------------	---

List of tables

Table 1-1:	Inclusion criteria	13
Table 7-1:	Summary of findings table of subcutaneous ICD compared with transvenous ICD in patients at high risk of sudden cardiac death	34
Table 9-1:	Evidence based recommendations	
Table A-1:	Subcutaneous versus transvenous ICD: Results from observational studies	43
Table A-2:	Risk of bias – study level (observational studies)	50
Table A-3:	Risk of bias – study level (systematic review)	51
Table A-4:	Evidence profile: comparative effectiveness and safety of the subcutaneous and transvenous ICD in patients at increased risk for sudden cardiac death	52
Table A-5:	Summary table characterising the applicability of a body of studies	54
Table A-6:	List of ongoing randomised controlled trials of subcutaneous ICD	54

List of abbreviations

ACC American College of Cardiology	LVEFLeft ventricular ejection fraction
AHA American Heart Association	MeSHMedical Subject Headings
AMSTAR A MeaSurement Tool to Assess systematic Reviews	MDMean difference/mittlere Differenz
ATP Antitachcardia pacing	NCDRNational Cardiovascular
ATLAS Avoid Transvenous Leads	Data Registry
in Appropriate Subjects	NCTNational Clinical Trials
CI Confidence interval	NICENational Institute for Health
CRD Centre for reviews and	and Care Excellence
dissemination	OROdds ratio
CRT Cardiac Resynchronization	PRISMA Preferred Reporting Items
Therapy	for Systematic Reviews and Meta-Analyses
ESC European Society	c c
of Cardiology	PRAETORIAN Prospective, RAndomizEd comparison of subcutaneous
ECG Electrocardiogram	and tRansvenous
EKG Elektrokardiogramm	ImplANtable cardioverter-
GRADE Grading of Recommendations Assessment, Development and	defibrillator therapy
Evaluation	QoLQuality of life
HRT Heart Rhythm Society	RRRisk ratio
HR Hazard ratio	RCTRandomized controlled trial
ICD-10-CM	S-ICD Subcutaneous Implantable
of Diseases, Tenth Revision,	Cardioverter-Defibrillator
Clinical Modification	SF-12Short Form Survey
ICDImplantable	SCDSudden Cardiac Death
Cardioverter-Defibrillator	TV Transvenous
KI Konfidenzintervall	VF Ventricular fibrillation
LVEF Left ventricular ejection fraction	VT Ventricular tachycardia

Executive Summary

Introduction

Health Problem

Cardiovascular disease is a major public health issue accounting for almost 17 million deaths per year globally. According to estimates, 40-50% of them are sudden cardiac deaths. Approximately 6 million sudden cardiac deaths are caused by ventricular tachyarrhythmias [1]. Several underlying acquired or congenital cardiac conditions are associated with an increased risk of ventricular arrhythmias.

Description of Technology

The implantable cardioverter-defibrillator (ICD) device detects and terminates these life-threatening ventricular tachyarrhythmias. Based on evidence from several trials, clinical practice guidelines of cardiological societies recommend the ICD in patients at high risk of developing ventricular tachyarrhythmia (primary prevention), or in patients who have experienced a prior episode of life-threatening ventricular tachyarrhythmias (secondary prevention).

Recently, the subcutaneous implantable ICD emerged as a promising alternative to the established transvenous ICD to overcome short- and long-term complications associated with the implantation of transvenous leads and direct contact with the heart. Specifically, such complications are pneumothorax, cardiac perforation, lead fracture, lead-dysfunction, infections (e.g. lead endocarditis) and venous thrombosis. The subcutaneous ICD leaves the heart and vascular system untouched. It is important to note, however, that the subcutaneous ICD is restricted to patient populations who are not dependent on pacing therapy for bradycardia, anti-tachycardia (ATP), or resynchronization (CRT).

Based on NICE (National Institute for Health and Care Excellence) guidance document, the current evidence on the efficacy and safety of subcutaneous ICD for preventing sudden cardiac death is adequate to support the use of this procedure [2].

Methods

We conducted a systematic literature review to evaluate the effectiveness and safety of the subcutaneous ICD compared to the conventional transvenous ICD in patients at an increased risk for sudden cardiac death due to an underlying acquired or congenital cardiac condition.

We searched four electronic databases: (Medline, Embase, Cochrane Library, CRD [Centre for reviews and dissemination]-Database).

In addition, we searched clinical trial registries and obtained relevant literature from the manufacturer. Two authors independently conducted study selection, data extraction, risk of bias assessment and rating of the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. sudden cardiac death: major public health issue common cause: ventricular tachyarrhythmias due to underlying cardiac conditions

Implantable cardioverterdefibrillator (ICD): established conventional ICD with transvenous lead(s)

promising relatively new alternative: ICD with subcutaneous leads

prerequisite:

no indication for pacing therapy for bradycardia, anti-tachycardia, or resynchronization

NICE guidance document: current evidence on efficacy and safety supports the use of the subcutaneous ICD

Research question: comparative effectiveness and safety of subcutaneous ICD vs. transvenous ICD

Electronic search in 4 databases

dual study selection, data extraction, risk of bias assessment and rating of the quality of evidence We synthesized evidence from identified individual studies narratively. In addition, we presented results from a random-effects meta-analysis from one systematic review [3]. Therefore, we did not perform any new meta-analysis.

Results

Available evidence

We found seven observational studies (6,916 patients) comparing the subcutaneous ICD with the conventional transvenous ICD [4-10], with the largest study including 5,760 patients [10]. In addition, we identified one systematic review and meta-analysis [3] including results from five of the aforementioned observational studies (6,498 patients) [4, 6, 7, 9, 10].

Two reviewers assessed the risk of bias of the included observational studies with the Newcastle-Ottawa Scale [11]. They rated the risk of bias as high for three studies [4, 6, 8] and medium for four studies [5, 7, 9, 10]. The systematic review was medium risk of bias based on our assessment with the AM-STAR (A MeaSurement Tool to Assess Systematic Reviews)-2 checklist [12].

In four studies, the control group was selected by propensity score matching [5, 7, 9, 10] in order to obtain similar groups. Three studies compared subcutaneous ICD only with a single-chamber transvenous ICD [4, 6, 8]. In four studies, patients in the control group received either single- or dual-chamber ICDs [5, 7, 9, 10].

Clinical effectiveness

Three studies with 6,222 patients reported on mortality [4, 7, 10]. The difference between patients receiving subcutaneous ICDs or transvenous ICDs was not statistically significant regarding overall mortality in-hospital (1 study, 5,760 patients, relative risk [RR] 2.0, 95% Confidence interval [CI]: 0.4-9.9) [10], mortality 6 months (1 study, 182 patients; RR 1.0; 95% CI: 0.14-6.95) [4] and mortality up to 5 years(1 study, 280 patients, 5-yearsurvival 96.0% vs. 94.8%, p = 0.42) [7].

Between patients receiving subcutaneous ICDs and transvenous ICDs, no statistical significant differences were observed regarding appropriate shocks during mean follow-up of 7.1 months (1 study, 138 patients, RR 0.33, 95% CI: 0.09-1.18) [6], 2.6 years (1 study, 138 patients, RR 0.60, 95% CI: 0.15-2.14) [9] and 5 years (1 study, 280 patients, hazard ratio [HR] 0.68, p = 0.36) [7].

Two studies with 418 patients found no statistically significant difference for mental quality of life assessed with 12-item Short-Form Health Survey (SF-12) after subcutaneous and transvenous ICD implantation [5, 8]. One study with 84 patients [8] observed statistically significantly higher physical quality of life in patients with subcutaneous ICDs (mean difference [MD] 6.7, 95% CI: 1.88-11.52) but another study with 334 patients [5] did not (MD -0.2, 95% CI: -2.67-2.27).

quality of evidence: very low The quality of evidence is very low for all effectiveness outcomes.

(n = 6,498 patients) risk of bias observational studies: high for 3 studies medium for 4 studies

effectivness and safety:

7 observations studies

(n = 6,916 patiens)

1 systematic review

subcutaneous ICD vs. transvenous single-chamber or dual-chamber ICD

effectiveness:

overall mortality,

rate of appropriate shock

and mental quality of life: no statistically

significant differences

7 studies

6

Safety

For inappropriate shocks (4 studies, 738 patients, Odds ratio [OR] 0.87, 95% CI: 0.51-1.49) [3], infections (5 studies, 6,498 patients, OR 0.75, 95% CI: 0.30-1.89) [3] and haematomas (3 studies, 6,080 patients, RR ranged from 3.00 to 3.5) [4, 6, 10] no statistically significant differences were observed in patients with subcutaneous ICD compared to patients with transvenous ICD.

However, random-effects meta-analyses showed statistically significant fewer lead-complications in patients with subcutaneous ICD compared to patients with transvenous ICD (4 studies, 6,316 patients, OR 0.13, 95% CI: 0.05-0.38) [3].

The quality of evidence for safety outcomes is very low.

Upcoming evidence

Our searches yielded the study protocol of an investigator-initiated, multicenter, randomized controlled PRAETORIAN (Prospective, RAndomizEd comparison of subcutaneous and tRansvenous ImplANtable cardioverter-defibrillator therapy) trial [13]. The planned sample size of this study is 850 patients with an indication for ICD therapy and without an indication for pacing, randomized to either the subcutaneous or transvenous ICD (1:1) [14]. This study is powered to claim non-inferiority and/or superiority of the subcutaneous ICD regarding a composite primary endpoint of inappropriate shocks and ICD-related complications (within 48 months). According to the ClinicalTrials.gov (NCT01296022) entry, the estimated completion date is December 2019 [14]. Thus, no results are available yet.

Discussion

The comparative evidence for the subcutaneous and transvenous ICD is limited to controlled observational studies with or without propensity-score matching and a systematic review with meta-analyses summarizing some of these studies. Based on this evidence, no statistically significant differences were observed in terms of overall mortality, rate of adequate and inadequate shocks, infections, and haematomas. Lead complications were statistically significantly less frequent in patients with subcutaneous ICDs compared to those with transvenous ICDs. It has to be considered that the subcutaneous ICD has no contact with vascular and cardiac structures. The quality of evidence is very low for all outcomes.

The available body of evidence has several limitations.

First, the follow-up periods varied considerably among the individual studies, ranging from a few days (duration of the hospital stay) to five years after ICD implantation. Therefore, most of the studies did not reflect long-term complications. Due to the variability of follow-up periods, pooled results from random-effects meta-analysis are limited.

Second, in several studies, despite matching, there were still differences of baseline characteristics between patients who received subcutaneous ICDs and patients who received conventional transvenous ICDs. In addition, not all studies clearly stated that they excluded patients with indications for pace-makers, anti-tachycardia pacing, or cardiac resynchronization therapy from the control group with transvenous ICDs. Therefore, unevenly distributed prognostic factors could have influenced the outcomes.

safety: 5 observational studies: no statistically significant differences for inappropriate shocks, infections and haematomas,

yet fewer lead complications with subcutaneous ICD

quality of evidence: Very low

ongoing RCT: PRAETORIAN trial (ClinicalTrials.gov NCT01296022) subcutaneous ICD vs. transvenous ICD

planned sample size: 850 patiens

completion estimated: December 2019

comparative evidence subcutanous ICD vs. transvenous ICD: 7 observational studies and 1 systematic review

risk of bias and other limitations:

different follow-up duration of included studies from in-hospital up to 5 years.

despite matching baseline characteristics different in some studies inprecision: only few events for most of the endpoints

results from large RCT are pending Third, for most effectiveness and safety endpoints, only few events occurred, limiting precision of the findings.

The PRAETORIAN study, an adequately powered randomized controlled trial (RCT), will provide more reliable information of the comparative effectiveness and harms of subcutaneous and transvenous ICDs.

Conclusion

current evidence insufficient to conclude about comparative effectiveness, however substantially lower risk for lead complications with subcutaneous ICD Results from seven observational studies and one systematic review are insufficient to conclude about the comparative effectiveness of subcutaneous and transvenous ICDs. These studies, however, indicate a substantially lower risk for lead complications in patients treated with subcutaneous ICD.

Zusammenfassung

Einleitung

Indikation und therapeutisches Ziel

Herz-Kreislauferkrankungen sind ein großes Public Health Problem – sie verursachen weltweit jährlich annähernd 17 Millionen Todesfälle. Schätzungen zufolge gelten 40-50 % dieser Todesfälle als plötzlicher Herztod [1]. Ungefähr 80 % davon, also ca. 6 Millionen Todesfälle durch plötzlichen Herztod, sind auf eine ventrikuläre Tachyarrhythmie zurückzuführen. Verschiedenste zugrundeliegende angeborene oder erworbene Herzerkrankungen sind mit einem erhöhten Risiko für das Auftreten von ventrikulären Tachyarrhythmien assoziiert.

Beschreibung der Technologie

Der implantierbare Cardioverter-Defibrillator (ICD) erkennt und unterbricht diese lebensbedrohlichen Herzrhythmusstörungen. Basierend auf den Ergebnissen zahlreicher Studien empfehlen kardiologische Fachgesellschaften den ICD bei PatientInnen mit erhöhtem Risiko für ventrikuläre Arrhythmien (primäre Prophylaxe) oder bei PatientInnen, die bereits eine Episode einer lebensbedrohlichen ventrikulären Tacharrhythmie hatten (sekundäre Prophylaxe).

Als vielversprechende Alternative zum seit Jahrzenten verwendeten transvenösen ICD steht seit einigen Jahren der subkutane ICD zur Verfügung, um Kurz- und Langzeitkomplikationen einer transvenös implantierten Sonde und den direkten Kontakt mit dem Herzen zu vermeiden. Zu den Komplikationen, die mit der Implantation einer tranvenösen Sonde einhergehen können, zählen insbesondere Ventrikelperforation, Penumothorax, Sondenbrüche, Isolationsdefekte der Sonden, Infektionen wie Sonden-Endokarditis und venöse Thrombosen. Voraussetzung für die Implantation eines subkutanen ICD ist jedoch, dass kein Stimulationsbedarf bei Bradykardie, kein Bedarf an antitachykarder Stimulation (antitachykardes Pacing, ATP) oder keine Indikation für eine Kardiale-Resynchronisationstherapie (CRT) besteht.

Laut einem NICE (National Institute for Health and Care Excellence) Dokument stützt die derzeitige Evidenz zur Wirksamkeit und Sicherheit die Verwendung des subkutanen ICD zur Prävention des plötzlichen Herztodes [2].

Methoden

Wir führten eine systematische Literaturübersicht durch. Ziel war es, die Wirksamkeit und Sicherheit des subkutanen ICD zur Verhinderung des plötzlichen Herztods mit der Wirksamkeit und Sicherheit des herkömmlichen transvenösen ICD zu vergleichen.

Wir führten zur Beantwortung der Forschungsfrage eine systematische Literatursuche in vier Datenbanken durch (Medline, Embase, Cochrane Library, CRD [Centre for reviews and dissemination]-Database). Ergänzend durchsuchten wir Studienregister und sendeten eine Anfrage an den Hersteller mit der Bitte um Zusendung relevanter Literatur. plötzlicher Herztod: Public Health Problem

häufigste Ursache: ventrikuläre Tachyarrhythmie aufgrund angeborener oder erworbener Herzerkrankungen

Implantierbarer Kardioverter-Defibrillator (ICD): etablierter konventioneller ICD mit transvenösen Sonden

relativ neu: ICD mit subkutaner Sonde

Voraussetzung: keine Indikation für Herzschrittmacher, antitachykarde Stimulation oder kardiale Resynchronisation

NICE Guidance Dokument: derzeitige Evidenz zeigt Wirksamkeit und Sicherheit

Forschungsfrage: Vergleich der Wirksamkeit und Sicherheit subkutaner ICD vs. transvenöser ICD

systematische Literatursuche in 4 Datenbanken duale Studienauswahl, Datenextraktion, Bewertung des Bias-Risikos sowie der Qualität der Evidenz nach GRADE Zwei AutorenInnen führten unabhängig voneinander die Studienauswahl, die Datenextraktion, die Bewertung der methodischen Qualität der Studien (Bias-Risiko) sowie der Qualität der Evidenz mit GRADE (Grading of Recommendations Assessment, Development and Evaluation) durch.

Die verfügbare Evidenz einzelner Studien fassten wir narrativ zusammen. Weiters beschreiben wir die Ergebnisse der Random-Effekts-Meta-Analysen einer systematischen Übersichtsarbeit [3]. Wir führten deshalb keine neuen Meta-Analysen durch.

Ergebnisse

Verfügbare Evidenz

Wir fanden sieben Beobachtungsstudien mit 6.916 PatientInnen, die subkutane ICD mit herkömmlichen transvenösen ICD verglichen [4-10], wobei die größte Studie 5.760 PatientInnen umfasste [10]. Weiters haben wir einen systematischen Review mit Meta-Analysen identifiziert [3].

Zwei Autoren bewerteten das Bias-Risiko der eingeschlossenen Beobachtungsstudien mit der Newcastle-Ottawa Scale [11]. Drei Studien [4, 6, 8] wurden mit hohem Bias-Risiko, vier Studien mit mittleren Bias-Risiko [5, 7, 9, 10] eingestuft. Den einzigen systematischen Review bewerteten wir mit niedrigem Bias-Risiko mittels der Checkliste AMSTAR-2 (A MeaSurement Tool to Assess systematic Reviews) [12].

In vier Studien [5, 7, 9, 10] wurde die Kontrollgruppe mittels Propensity Score ausgewählt, um Gruppen zu erhalten, die ein ähnliches Risiko aufweisen, an einem plötzlichen Herztod zu versterben. Drei Studien verglichen den subkutanen ICD mit einem transvenösen Einkammer-ICD [4, 6, 8]. In vier weiteren Studien erhielten die PatientInnen der Kontrollgruppe sowohl Einals auch Zweikammer-ICDs [5, 7, 9, 10].

Klinische Wirksamkeit

Drei Studien mit 6.222 PatientInnen berichten über Mortalität [4, 7, 10]. Der Unterschied zwischen PatientInnen, die einen subkutanen ICD oder einen transvenösen ICD bekommen hatten, war in Hinblick auf die Mortalität im Krankenhaus (1 Studie, 5.760 PatientInnen, Relatives Risiko [RR] 2,0, 95 % Konfidenzintervall [KI]: 0,4-9,9) [10], Mortalität nach 6 Monaten (1 Studie, 182 PatientInnen, RR 1,0, 95 % KI: 0,14-6,95) [4] und Mortalität bis 5 Jahre (1 Studie, 280 PatientInnen, 5-Jahres-Überleben: 96 % vs. 94,8 %, p = 0,42) statistisch nicht signifikant [7].

Der Unterschied bei adäquaten Schocks zwischen PatientInnen, die einen subkutanen ICD und PatientInnen, die einen transvenösen ICD erhielten, war bei einer mittleren Beobachtungszeit von 7.1 Monaten (1 Studie, 138 PatientInnen, RR 0,33, 95 % KI: 0,09-1,18) [6], 2.6 Jahren (1 Studie, 138 PatientInnen, RR 0,60, 95 % KI: 1,15-2,14) [9] sowie 5 Jahren (1 Studie, 280 PatientInnen, Hazard Ratio [HR] 0,68, p = 0,36) [7] statistisch nicht signifikant.

Die mentale Lebensqualität, die mittels 12-item Short-Form Health Survery (SF-12) erhoben wurde, war in zwei Studien mit 418 PatientInnen nicht statistisch signifikant unterschiedlich [5, 8]. Bei der physischen Lebensqualität zeigte eine Studie mit 84 PatientInnen [8] einen statistisch signifikant höheren Score bei PatientInnen mit subkutanem ICD (mittlere Differenz [MD] 6,7, 95 % KI: 1,88-11,52), eine andere Studie mit 334 PatientInnen [5] jedoch nicht (MD -0,2, 95 % CI: -2,67-2,27).

verfügbare Evidenz: Wirksamkeit und Sicherheit : 7 vergleichende Beobachtungsstudien (n = 6.916 PatientInnen) 1 Systematischer Review (n = 6.498 PatientInnen)

Bias-Risiko der eingeschlossenen Beobachtungsstudien: hoch für 3 Studien medium für 4 Studien

Matching mit Propensity-Score: 4 Studien

Subkutaner ICD vs. transvenöser Einoder Zweikammer-ICD

Wirksamkeit: 7 Beobachtungs-studien

Gesamtmortalität, adäquate Schocks und mentale Lebensqualität: kein statistisch signifikanter Unterschied Die Qualität der Evidenz für die oben genannten Endpunkte ist sehr niedrig.

Sicherheit

Inadäquate Schocks (4 Studien, 738 PatientInnen, Odds Ratio [OR] 0,87, 95 % KI: 0,51-1,49) [3], Infektionen (5 Studien [3], 6.489 PatientInnen, OR 0,75, 95 % KI: 0,30-1,89) und Hämatome (3 Studien, 6.080 PatientInnen, RR von 3,00 bis 3,5) [4, 6, 10] waren nicht statistisch signifikant unterschiedlich bei PatientInnen mit subkutanen im Vergleich zu PatientInnen mit transvenösen ICD.

Jedoch ergab eine Meta-Analyse statistisch signifikant weniger Sondenkomplikationen mit dem subkutanen ICD als mit dem transvenösen ICD (4 Studien, 6.316 PatientInnen, OR 0,13, 95 % KI: 0,05-0,38) [3].

Die Qualität der Evidenz ist sehr niedrig für alle Sicherheits-Endpunkte.

Laufende Studien

Bei unserer Suche haben wir das Studienprotokoll der randomisiert kontrollierten Multicenter-Studie PRAETORIAN (Prospective, RAndomizEd comparison of subcutaneous and tRansvenous ImplANtable cardioverter-defibrillator therapy) gefunden [13]. Diese Studie plant 850 PatientInnen mit Indikationen für einen ICD, zu einem subkutanen oder transvenösen ICD zu randomisieren (1:1) [14]. Die Fallzahl wurde berechnet um Nichtunterlegenheit und/oder Überlegenheit des subkutanen ICD in Bezug auf einen kombinierten, primären Endpunkt (inadäquater Schock oder ICD-assoziierte Komplikationen innerhalb von 48 Monaten) zu zeigen. Nach dem ClinicalTrials.gov Eintrag (NCT01296022) wird die Studie voraussichtlich im Dezember 2019 beendet [14]. Deshalb liegen derzeit noch keine Resultate vor.

Diskussion

Wie dieser Review zeigt, ist die Evidenz bezüglich Vergleichs des subkutanen mit dem transvenösen ICD auf kontrollierte Beobachtungsstudien mit oder ohne Propensity-Score-Matching beschränkt. Ein rezent publizierter Systematischer Review mit Meta-Analysen hat die Ergebnisse einiger dieser Studien zusammengefasst und analysiert. Die vorliegende Evidenz zeigte keinen statistisch signifikanten Unterschied bei PatientInnen, die einen subkutanen ICD oder einen transvenösen Ein- oder Zweikammer-ICD erhielten in Bezug auf Gesamtmortalität, adäquaten und inadäquaten Schocks, Infektionen, Hämatome, und mentaler Lebensqualität. Sondenkomplikationen waren jedoch statistisch signifikant seltener bei PatientInnen, die einen subkutanen ICD erhalten hatten als bei PatientInnen mit transvenösem ICD. Dabei muss berücksichtig werden, dass bei einem subkutanen ICD die Sonde nicht transvenös platziert wird und auch kein direkter Kontakt mit kardialen Strukturen besteht.

Die verfügbare Evidenz hat einige Einschränkungen.

Der Beobachtungszeitraum unterscheidet sich deutlich zwischen den einzelnen Studien und reichte von der Dauer des Krankenhausaufenthaltes bis zu fünf Jahre nach ICD-Implantation. Deshalb könnte es sein, dass in den meisten Studien Langzeitkomplikationen nicht abgebildet wurden. Außerdem sind aufgrund der Variabilität des Follow-Up-Zeitraumes die Ergebnisse der Random-Effects-Meta-Analyse nur eingeschränkt aussagekräftig. Sicherheit: 5 Beobachtungsstudien: kein statistisch signifikanter Unterschied bei inadäquaten Schocks, Infektionen und Hämatomen; Sondenkomplikationen statistisch signifikant seltener mit subkutanem ICD; Qualität der Evidenz: sehr niedrig

laufender RCT: PRAETORIAN trial (ClinicalTrials.gov NCT01296022) Subkutaner vs. transvenöser ICD Geplante Anzahl an StudienteilnehmerInnen: 850 PatientInnen Voraussichtliches Ende: Dezember 2019

Vergleichsstudien subkutaner ICD vs. transvenöser ICD: 7 Beobachtungsstudien und 1 Systematischer Review

Bias-Risiko und andere Einschränkungen

unterschiedliche Beobachtungszeiträume der Studien Baseline-PatientInnen-Charakteristika trotz Matching unterschiedlich in manchen Studien

eingeschränkte Präzision aufgrund weniger Ergebnisse bei einigen Endpunkten Trotz Matching zeigten sich in einigen Studien teilweise bei den Baseline-Charakteristika Unterschiede zwischen PatientInnen, die einen subkutanen ICD erhielten und PatientInnen, bei denen ein herkömmlicher transvenöser ICD implantiert wurde. Hervorzuheben ist weiters, dass nicht alle Studien PatientInnen in der Kontrollgruppe mit transvenösem ICD mit Indikation für Herzschrittmacher, antitachykarde Stimulation oder kardialer Resynchronisations-Therapie ausschlossen. Deshalb könnten ungleichmäßig verteilte prognostische Faktoren die Ergebnisse beeinflusst haben.

Beim Großteil der Endpunkte für Wirksamkeit und Sicherheit traten nur wenige Ereignisse auf, was die Präzision der Ergebnisse einschränkt.

Die derzeit laufende randomisiert kontrollierte PRAETORIAN-Studie mit adäquater Power könnte verlässlichere Ergebnisse zum Vergleich des subkutanen ICD mit dem transvenösen ICD liefern.

Empfehlung

Evidenz derzeit unzureichend für den Vergleich der Wirksamkeit, jedoch deutlich geringeres Risiko für Sondenkomplikationen mit subkutanen ICD Die vorliegenden Ergebnisse aus sieben Beobachtungsstudien sind unzureichend, um eine Aussage über die Wirksamkeit des subkutanen ICDs im Vergleich zum transvenösen ICD treffen zu können. Diese Studien zeigten jedoch statistisch signifikant weniger Sondenkomplikationen bei PatientInnen, die einen subkutanen ICD erhielten.

1 Scope

1.1 PICO question

Is the subcutaneous ICD compared to the conventional transvenous ICD equally or more effective and/or safer for the prevention of sudden cardiac death in patients at an increased risk?

1.2 Inclusion criteria

Table 1-1 summarizes the inclusion criteria for relevant studies.

Einschlusskriterien für relevante Studien

Table 1-1: Inclusion criteria

P opulation	Adults (18 years or older) with an underlying cardiac condition/disease associated with an increased risk of sudden cardiac death and indication for an implantable cardioverter-defibrillator for primary or secondary prevention.		
	According to the European Society of Cardiology (ESC) guideline, primary and secondary prevention are defined as follows [15]:		
	<i>Primary prevention of sudden cardiac death:</i> Therapies to reduce the risk of sudden cardiac death in individuals who are at risk of sudden cardiac death but have not yet experienced an aborted cardiac arrest or life-threatening arrhythmias [15]		
	Secondary prevention of sudden cardiac death: Therapies to reduce the risk of sudden cardiac death in patients who have already experienced an aborted cardiac arrest or life-threatening arrhythmias [15]		
	2018 ICD-10-CM Diagnosis Code: 146.2 Cardiac arrest due to underlying cardiac condition MeSH terms: Death, Sudden, Cardiac (Tree Numbers: C14.280.383.220, C23.550.260.322.250, MeSH Unique ID: D016757)		
Intervention	Subcutaneously implantable cardioverter-defibrillator (ICD) 2018 ICD-10-CM Diagnosis Code: Z95.810 Presence of automatic (implantable) cardiac defibrillator MeSH terms: Defibrillators, Implantable (Tree Numbers: E07.305.250.159.175,		
C ontrol	E07.305.250.319.175, E07.695.202.175, MeSH Unique ID: D017147) Single- or dual-chamber, conventional transvenous implantable		
	cardioverter-defibrillator (ICD) Rationale: The transvenous ICD is an established and broadly used device for primary and secondary prevention in patients at risk of sudden cardiac death. Several randomized controlled trials have demonstrated its benefit.		
Outcomes	Rationale: For selection of relevant outcomes reflecting benefit and harms, we relied primarily on a recently-published systematic review [3].		
Effectiveness	 All-cause mortality Appropriate shocks 		
Safety	 Inappropriate shocks Lead complications Infections Haematoma 		
	Pericardial tamponade		

S tudy design	
Effectiveness	Randomized controlled trials A Observational studies with control around
	 Observational studies with control group Systematic reviews
	Excluded: conference abstracts, narrative reviews, letters to the editor, case reports, case series, retrospective and prospective single-arm studies
Safety	 Randomized controlled trials Observational studies with control group Systematic reviews
	Excluded: conference abstracts, narrative reviews, letters to the editor, case reports, retrospective and prospective single-arm studies

2 Methods

2.1 Research questions

Description o	Description of the technology		
Element ID	Research question		
B0001	What is the subcutaneous ICD and the transvenous ICD?		
A0020	For which indications has the technology received marketing authorisation or CE marking?		
B0002	What is the claimed benefit of subcutaneous ICD in relation to the transvenous ICD?		
B0003	What is the phase of development and implementation of the subcutaneous ICD and the transvenous?		
B0004	Who administers the subcutaneous ICD and transvenous ICD and in what context and level of care are they provided?		
B0008	What kind of special premises are needed to use the subcutaneous ICD and transvenous ICD?		
B0009	What supplies are needed to use the subcutaneous ICD and transvenous ICD?		
A0021	What is the reimbursement status of the subcutaneous ICD?		

Health problem and Current Use			
Element ID	Research question		
A0001	For which health conditions, and for what purposes is the subcutaneous ICD used?		
A0002	What is the disease or health condition in the scope of this assessment?		
A0003	What are the known risk factors for the disease or health condition?		
A0004	What is the natural course of the disease or health condition?		
A0005	What is the burden of disease for the patients with the disease or health condition?		
A0006	What are the consequences of the disease or health condition for the society?		
A0024	How is the disease or health condition currently diagnosed according to published guidelines and in practice?		
A0025	How is the disease or health condition currently managed according to published guidelines and in practice?		
A0007	What is the target population for this assessment?		
A0023	How many people belong to the target population?		
A0011	How much are the technologies utilised?		

Clinical Effect	tiveness		
Element ID	Research question		
D0001	What is the expected beneficial effect of the subcutaneous ICD on mortality? How does the subcutaneous ICD affect symptoms and findings (severity, frequency) of the disease or health condition?		
D0005			
D0006	How does the technology affect progression (or recurrence) of the disease or health condition?		
D0011	What is the effect of the technology on patients' body functions?How does the use of technology affect activities of daily living?		
D0016			
D0012	What is the effect of the subcutaneous ICD on generic health-related quality of life?		
D0013	What is the effect of the t subcutaneous ICD on disease-specific quality of life?		

Safety			
Element ID	nt ID Research question		
C0008	How safe is the subcutaneous ICD in comparison to the transvenous ICD?Are the harms related to dosage or frequency of applying the technology?		
C0002			
Cooo4How does the frequency or severity of harms change over time or in different settingsCooo5What are the susceptible patient groups that are more likely to be harmed through the of the subcutaneous ICD?			
		C0007	Are the subcutaneous ICD and transvenous ICD associated with user-dependent harms?

2.2 Sources

Description of the technology, health problem and current use

Quellen

- Background publications identified by database search (see Section 2.3) and hand search
- Clinical practice guidelines identified by hand search
- Hand search in the POP (Planned and Ongoing Projects), AdHopHTA (Adopting Hospital-based Health Technology Assessment) and CRD (Centre for Reviews and Dissemination) databases for Health Technology Assessments
- Documentation provided by the manufacturer

2.3 Systematic literature search

systematische Literatursuche in	The systematic literature search was conducted on November 23, 2017 in the following databases:		
4 Datenbanken	🕆 Pubmed		
	Embase.com (Elsevier)		
	The Cochrane Library (Wiley)		
	CRD (Centre for Reviews and Dissemination) Databases:		
	DARE (Database of Abstracts of Reviews of Effects),		
	 NHS-EED (National Health System-Economic Evaluation) Database 		
	🏶 HTA (Health Technology Assessment) Database		
	The systematic search was limited to the years 2000 to 2017. After dedupli- cation, 569 citations were included overall. The specific search strategy em- ployed can be found in the Appendix p55.		
Suche nach laufenden Studien; Kontaktaufnahme mit Herstellern	Furthermore, to identify ongoing and unpublished studies, a search in three linical trials registries (ClinicalTrials.gov; WHO-ICTRP [World Health Organization International Clinical Trials Registry Platform]); EU Clinical Trials) was conducted on November 23, 2017, resulting in 20 potential rele- ant hits after deduplication.		

We screened 139 references submitted by the manufacturer of approved subcutaneous ICDs (Boston Scientific). 740 Referenzen identifiziert

By hand-search, 12 additional references were found, resulting in 740 citations overall.

2.4 Flow chart of study selection

Overall, 740 citations were identified after the removal of duplicates. The references were screened by two independent researchers (GW, AG) and, in case of disagreement, a third researcher was involved to resolve the differences. The selection process is displayed in Figure 2-1.

Literaturauswahl




Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram)

2.5 Analysis

Datenextraktion in Tabellen

Zusammenfassung der Ergebnisse einer Random-Effects Meta-Analyse eines rezent publizierten systematischen Reviews

Risk of Bias Bewertung mit Newcastle-Ottawa Scale und AMSTAR-2 We calculated relative risk for binary outcomes if appropriate. Two researchers (GW, TS) conducted risk of bias assessments independently. For observational studies they used the Newcastle-Ottawa Scale [11] (see Ta-

We extracted data from included studies into data extraction tables based on

the study design and research question (see Appendix Table A-1). An inde-

In addition to data from seven observational studies, we obtained data from

the meta-analysis of one systematic review. We did not conduct any additional meta-analysis. We used mean quality of life scores and standard deviations

pendent second reviewer (TS, EP) validated the data for accuracy.

to calculate mean differences and 95% confidence intervals.

For observational studies they used the Newcastle-Ottawa Scale [11] (see Table A-2); for the systematic reviews, AMSTAR-2 (Assessing the Methodological Quality of Systematic Reviews) [12](see Table A-3). We resolved differences by consensus.

2.6 Synthesis

Zusammenfassung der Ergebnisse

Bewertung der Qualität der Evidenz mit GRADE Based on the data-extraction-table (see Appendix Table A-1), data on each selected outcome were synthesized. Quality of evidence was assessed across studies for each outcome according to GRADE (Grading of Recommendations Assessment, Development and Evaluation) [16]. The research questions were answered in plain text format with reference to GRADE evidence tables (see Table A-4).

3 Description and technical characteristics of technology

Features of the technology and comparators

B0001 – What is the subcutaneous and the transvenous ICD?

The subcutaneous ICD and the transvenous ICD continuously monitor heart rate and deliver shock therapy in the event of life-threatening tachycardia, and convert the abnormal heart rhythm back to normal [17].

Subcutaneous ICDs differ from transvenous ICDs in that the lead is placed subcutaneously i.e. directly under the skin rather than transvenously and is not directly attached to the heart [18]. The subcutaneous ICD senses cardiac signals, however, is not designed to provide long-term pacing [2].

Subcutaneous ICDs consist of a pulse generator placed on the left side of the chest at the mid-axillary line between the fifth and sixth intercostal spaces. A lead with two sensing electrodes and a shocking coil, which can defibrillate most patients at 80 Joule, are placed subcutaneously adjacent to the sternum [15]. The pulse generator housing serves as an electrode for defibrillation and can also serve as an optional electrode for sensing.

Patients need to undergo an ECG to assess QRS-T wave morphology prior to implant to check for susceptibility to under-sensing of ventricular tachycardia/ventricular fibrillation and inappropriate shocks [17].

A drawback of the subcutaneous ICD is T-wave oversensing which can lead to inappropriate therapy [19]. Other potential causes of oversensing are electromagnetic interference or myopotentials.

Other limitations are the lack of evidence regarding long-term durability/ longevity of subcutaneous ICD leads and experience regarding lead re-interventions.

Transvenous ICDs consist of a generator, which is usually implanted in a pocket in the pectoral region below the left shoulder, and a transvenous right ventricular lead containing the shock coils and pacing electrode. Additional leads may be connected to right atrial or left ventricular pacing, sensing, and defibrillation. The leads are inserted through an incision into a vein and guided to the heart under fluoroscopic guidance. The lead tip is attached to the heart, while the other end of the lead is attached to the pulse generator [17, 20]

A0020 – For which indications has subcutaneous ICD received marketing authorisation or CE marking?

The Cameron Health subcutaneous ICD system (later bought by Boston Scientific) received CE-marking (CE: 623289) in 2009 for use in eligible patients for the prevention of sudden cardiac death. The second generation EMBLEM[™] S-ICD System and EMBLEM MRI S-ICD system received CE marking in 2015. subkutaner und transvenöser ICD:

detektieren und beenden lebensbedrohliche Tachyarrhytmien durch Schockabgabe

implantierbarer Kardioverter-Defibrillator (ICD): Etablierter konventioneller ICD mit transvenösen Sonden

Subkutaner ICD: T-Wellen Oversensing

keine Daten zur Langzeithaltbarkeit der Sonde und wenig Erfahrung mit Sonden Re-Interventionen

Indikation: Prävention des plötzlichen Herztodes

B0002 – What is the claimed benefit of the subcutaneous ICD in relation to the transvenous ICD?

Subcutaneous ICD technology enables the implantation of a defibrillator system without transvenous ICD leads. The lead is placed subcutaneously rather than transvenously and is not directly attached to the heart, which avoids problems associated with accessing the heart via the vascular system and complications with the transvenous leads of the transvenous ICD system [15]. Specifically, such complications are pneumothorax, cardiac perforation, lead fracture, lead dysfunction, infections (e.g. lead endocarditis) and venous thrombosis. Implantation is done via primarily anatomical landmarks, minimizing the need for fluoroscopy [17].

Booo3 – What is the phase of development and implementation of the subcutaneous ICD and transvenous ICD?

Subkutaner ICD: 2009 CE-Kennzeichnung 2012 FDA Zulassung 2015 CE Kennzeichnung EMBLEM[™] S-ICD

Vorteile des

subkutanen ICD:

keine Implantation einer

transvenösen Sonde

direkter Kontakt mit

kardialen Strukturen

und dadurch auch kein

Transvenöser ICD: Seit fast 30 Jahren implantiert Wirksamkeit mehrfach in RCTs gezeigt

Implantation:

HerzchirurgIn Herzkatheterlabor

interventionelle/r

Kardiologe/In oder

oder Operationssaal

Implantation unter

Regionalanästhesie

Erfahrene/r

Subcutaneous ICD was introduced in human feasibility trials in 2002 and

now in use for almost three decades and is an established and broadly used medical device. Several trials have demonstrated its benefit in primary or secondary prevention patient populations [22-24].

Administration, Investments, personnel and tools required to use the technology and the comparator(s)

B0004 – Who administers the subcutaneous ICD and transvenous ICD and in what context and level of care are they provided?

The subcutaneous and transvenous ICD is implanted by a cardiologist or a cardiac surgeon experienced in implanting these devices.

B0008 – What kind of special premises are needed to use the subcutaneous and transvenous ICD?

Both devices, the subcutaneous and transvenous ICDs, are usually implanted at a cardiac catheterisation laboratory or in an operating theater.

Booog – What supplies are needed to use subcutaneous ICD and transvenous ICD?

For ICD implantation, patients are monitored by an anaesthesiologist and usually receive regional anaesthesia with analgosedation. The implantation procedure is performed under sterile conditions. The implanting physician is supported by specialized trained assistance/nurses.

Regulatory & reimbursement status

A0021 – What is the reimbursement status of the subcutaneous ICD?

derzeit nicht im Leistungskatalog abgebildet The subcutaneous ICD does not yet have its own settlement rate and is currently being billed as a transvenous single or dual-chamber ICD.

clinical trials in 2008. Subcutaneous ICD later received CE marking in 2009. Food and Drug Administration (FDA) approval was obtained in September 2012. The second generation EMBLEM[™] S-ICD system and EMBLEM[™] MRI S-ICD system were introduced in 2015. The use of the subcutaneous ICD in clinical practice is constantly increasing. After first human implantation in 1980 [21], the transvenous ICD has been

4 Health Problem and Current Use

Overview of the disease or health condition

A0001 – For which health conditions, and for what purposes is subcutaneous ICD used?

Both transvenous and subcutaneous ICDs are implanted in patients at risk of sudden cardiac death. Ischemic heart disease is the leading structural heart disease, however, non-ischemic cardiomyopathy and other structural abnormalities, such as arrhythmogenic ventricular dysplasia and hypertrophic cardiomyopathy, may also cause sudden cardiac death [2].

Subcutaneous ICDs cannot achieve adequate arrhythmia sensing for all patients, and neither provide bradycardia nor anti-tachycardia pacing, which are both possible with the transvenous ICD [17]. Thus, patients requiring bradycardia pacing are not suitable candidates for subcutaneous ICDs, unless pacing is only required immediately after shock delivery, as transcutaneous pacing can be delivered for 30 seconds after the shock. Patients suffering from tachyarrhythmia that is easily resolved by anti-tachycardia pacing, and patients needing cardiac resynchronization therapy, are also not candidates for subcutaneous ICDs [15].

Potential candidates for subcutaneous ICDs include paediatric patients with congenital heart disease, those with difficult venous access (obstruction, venous abnormality), chronic indwelling catheters, high infection risk, or young patients with electrical heart disease (e.g. Brugada Syndrome, long QT syndrome, short QT syndrome, and hypertrophic cardiomyopathy) [25].

A0002 – What is the disease or health condition in the scope of this assessment?

Primary and secondary prevention of sudden cardiac death.

The term sudden cardiac death is defined as [15]:

- A congenital, or acquired, potentially fatal cardiac condition known to be present in life; or
- Autopsy results showing cardiac or vascular anomaly as the probable cause of the event; or
- No obvious extra-cardiac causes found during post-mortem examination and therefore an arrhythmic event is likely the cause of death.

A0003 – What are the known risk factors for the disease or health condition?

In younger patients, channelopathies, myocarditis, cardiomyopathies, and substance abuse are the predominant cardiac diseases associated with sudden cardiac death [15].

In older patients, the presence of chronic degenerative diseases, such as valvular heart diseases, coronary artery diseases (CAD), and heart failure (HF), are the main causes of sudden cardiac death [15]. verschiedene angeborene oder erworbene Herzerkrankungen führen zu einem erhöhten Risiko für plötzlichen Herztod

Subkutaner ICD: Voraussetzung keine Indikation für Herzschrittmacher, antitachykarde Stimulation oder kardiale Resynchronisation

Anwendung des subkutanen ICD zB bei komplizierten Venenzugang, hohem Infektionsrisiko, junge PatientInnen mit Ionenkanalerkrankungen oder Kardiomyopathie

Primäre und sekundäre Prävention des plötzlichen Herztodes

junge PatientInnen: Ionenkanalerkrankungen, Myokarditis, Kardiomyopathien ältere PatientInnen: Koronare Herzkrankheit, Herzklappen erkrankungen, Herzinsuffizienz

Effects of the disease or health condition on the individual and society

A0005 – What is the burden of disease for patients with the disease or health condition?

Cardiovascular disease is a major public health issue accounting for almost 17 million deaths per year globally. According to estimates, 40-50% of deaths are sudden cardiac deaths, with approximately 80% (6 millions) of them due to ventricular tachyarrhythmias [1].

Several underlying acquired or congenital cardiac conditions are associated with an increased risk of ventricular arrhythmias.

A0006 – What are the consequences of the disease or health condition for the society?

In one observational study with 138 patients, the mean cost per patient including implant and complication costs was £12,601 \pm 1,786 for the subcutaneous ICD and £9,967 \pm 4,511 for the transvenous ICD (p = 0.0001) [9].

Current clinical management of the disease or health condition

A0024 — How is the disease or health condition currently diagnosed according to published guidelines and in practice?

Clinical history, physical examination and electrocardiogram (ECG) are the first step in diagnostic algorithm of congenital and acquired cardiac disease. Echocardiography is recommended for assessment of left ventricular function and detection of structural heart disease. Coronary angiography is applied in patients with suspected coronary artery disease (CAD).

Additional patient assessment, e.g. stress test, holter 48 hours, cardiovascular magnetic resonance imaging, drug challenges, electrophysiological study or genetic testing is performed according to suspected cardiac condition.

A0025 – How is the disease or health condition currently managed according to published guidelines and in practice?

In general, ICD is recommend for primary prevention of sudden cardiac death in certain patients with ischaemic cardiomyopathy, post myocardial infarction, non-ischaemic cardiomyopathy, inherited arrhythmia syndromes or inherited cardiomyopathies. In patients with history of cardiac arrest or lifethreating ventricular arrhythmia ICD is recommended for secondary prevention of sudden cardiac death if certain criteria are met. Usually transvenous ICDs systems are implanted, however, guidelines recommend to consider the use of the subcutaneous ICD as follows [15]:

- Subcutaneous ICDs should be considered as an alternative to transvenous ICDs in patients with an indication for an ICD when pacing therapy for bradycardia support, cardiac resynchronization or anti-tachycardia pacing is not needed. (Class IIa, Level C)
- The subcutaneous ICD may be considered as a useful alternative to the transvenous ICD system when venous access is difficult, after the removal of a transvenous ICD for infections or in young patients with a long-term need for ICD therapy (Class IIa, Level C)

The 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death state the following recommendations [17]:

sudden cardiac death: major public health issue common cause: ventricular tachyarhythmias due to underlying cardiac conditions

Basisdiagnostik: Anamnese, Physikalische Krankenuntersuchung, EKG, Echokardiographie

> weitere Abklärung je nach Verdachtsdiagnose

ESC Leitlinie: Subkutaner ICD sollte bei Patientinnen ohne Notwenigkeit für Schrittmacher, antitachykardes Pacing oder Resynchronisations Therapie erwogen werden (Klasse IIa, Level C) kann bei schwierigem Venenzugang, nach Entfernung eines transvenösen ICDs aufgrund einer Infektion oder bei jungen PatientInnen erwogen werden (Klasse IIa, Level C

- In patients who meet criteria for an ICD who have inadequate vascular access or are at high risk for infection, and in whom pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated, a subcutaneous implantable cardioverter-defibrillator is recommended (Class I, Level B)
- In patients who meet indication for an ICD, implantation of a subcutaneous implantable cardioverter-defibrillator is reasonable if pacing for bradycardia or VT termination or as part of CRT is neither needed nor anticipated (Class IIa, Level B)

Based on NICE (National Institute for Health and Care Excellence) guidance document, current evidence on the efficacy and safety of subcutaneous ICD for preventing sudden cardiac death is adequate to support the use of this procedure [2].

Target population

A0007 – What is the target population in this assessment?

Patients with congenital or acquired cardiac disease at high risk for sudden cardiac death.

According to the European Society of Cardiology (ESC) guideline, primary and secondary prevention are defined as follows [15]:

- Primary prevention of sudden cardiac death: Therapies to reduce the risk of sudden cardiac death in individuals who are at risk of sudden cardiac death but have not yet experienced an aborted cardiac arrest or life-threatening arrhythmias [15]
- Secondary prevention of sudden cardiac death: Therapies to reduce the risk of sudden cardiac death in patients who have already experienced an aborted cardiac arrest or life-threatening arrhythmias [15]

A0023 – How many people belong to the target population?

A0011 – How much is the subcutaneous ICD utilised?

It is estimated that up to 55% of patients with an ICD indication are potential candidates for a subcutaneous device in clinical practice [26].

Based on the statistical report from the European Heart Rhythm Association, in Austria, 1,296 ICDs were implanted in the year 2013 [27].

In the United States, based on the National Cardiovascular Data Registry (ICD Registry), 393,734 ICDs were implanted between September 28, 2012 and March 31, 2015. Among them, 3,717 (0.9%) were subcutaneous ICDs [10].

AHA/ACC/HRS Leitlinie 2017 Empfehlungen: Klasse I, Level B Klasse IIa, Level B

NICE Guidance Dokument: derzeitige Evidenz zeigt Wirksamkeit und Sicherheit des subkutanen ICDs

PatientInnen mit angeborenere oder erworberener Herzerkrankung die mit einem erhöhten Risiko des plötzlichen Herztodes assoziiert sind

Primäre oder sekundäre Prävention des plötzlichen Herztodes

Österreich: 2013: 1.296 ICD Implantationen

USA:

>390.000 ICD Implantationen in 2,5 Jahren, davon 3.717 (0,9 %) subkutane ICDs

5 Clinical effectiveness

5.1 Outcomes

The following outcomes were defined as *crucial* to derive a recommendation:

- All-cause mortality
- Appropriate shock
 Appropriate shock is usually defined as a shock delivery for ventricular tachycardia or ventricular fibrillation.

5.2 Included studies

We identified seven eligible observational studies with 6,916 patients [4-10] and one systematic review [3] addressing our research question. From the systematic review we obtained results of quantitative analysis (meta-analyses).

Our search also identified a second systematic review, but it did not include recently published studies comparing the subcutaneous with the transvenous ICD [28].

Study characteristics and results of included studies are displayed in Table A-1 and in the evidence profile in Table A-4

The maximum follow-up in the studies ranged from the duration of the hospital stay to five years after implantation. In four studies, the control group was selected by propensity score matching [5, 7, 9, 10] in order to obtain similar groups. Three studies compared a subcutaneous ICD with a single-chamber transvenous ICD [4, 6, 8]. In four studies, patients in the control group received either single- or dual-chamber ICDs [5, 7, 9, 10].

The largest retrospective observational study involving a total of 5,760 patients from the National Cardiovascular Data Registry (NCDR) ICD Registry compared the effectiveness and safety of the subcutaneous ICD to the singlechamber ICD and dual-chamber ICD for multiple clinical endpoints during hospitalization [10]. Propensity score matching took into account implantation date, patient characteristics, and physician characteristics.

The other retrospective observational studies had longer observation periods but analyzed significantly fewer patients.

eingeschlossene Publikationen: 7 Beobachtungsstudien mit 6.916 PatientInnen

1 Systematischer Review mit Meta-Analyse aus 5 dieser Beobachtungsstudien

Follow-up Zeitraum der identifizierten Studien sehr variabel: Krankenhausaufenthalt bis 5 Jahre

größte retrospektive Beobachtungsstudie mit Propensity Score Matching analysierte Daten von 5.760 PatientInnen aus dem NCDR ICD Register

5.3 Results

Mortality

Dooo1 – What is the expected beneficial effect of the subcutaneous ICD on mortality?

All-cause mortality

Three retrospective observational studies with 6,222 patients [4, 7, 10] showed no statistically significant differences in mortality. Two of the studies performed propensity score matching [7, 10].

In all three studies, there were no statistically significant differences in mortality rates between the two groups. In the largest observational study involving a total of 5,760 patients, 0.2% (3 of 1,920) died during hospitalization in the subcutaneous ICD group, 0.1% (2 of 1,920; p > 0.99) in the single-chamber ICD group, and 0.05% (1 of 1,920, p = 0.64) in patients with dual-chamber ICD. No statistically significant differences were found if patients with subcutaneous ICD compared to all patients with transvenous ICD (3 of 1920 vs. 3 of 3840; relative risk [RR] 2.0, 95% confidence interval [CI]: 0.4-9.9, [selfcalculated]) [10].

Studien mit längsterIn a smBeobachtungszeit undCI: 90.280 PatientInnen:CI: 90.5-Jahres-Überleben:pacema96,0 % vs. 94,8 %,ventionp = 0,42transver

p > 0,99

Gesamtmortalität:

Größte Studien mit

5.760 Patientinnen

Krankenhausmortalität 0,2 % vs. 0,1 %,

kein statistisch

signifikanter

Unterschied

3 Beobachtungsstudien,

In a smaller study with 280 participants, 5-year survival rate was 96.0% (95% CI: 90.1-100.0%) in the subcutaneous ICD group compared to 94.8% (95% CI: 90.7-99.0%) in the transvenous ICD group (p = 0.42) [7]. Patients with pacemaker indication were not excluded in the group of patients with conventional ICD and the mean observation period of the subcutaneous and transvenous group was different (5 years vs. 3 years) [7].

Morbidity

Dooo5 – How does the subcutaneous ICD affect symptoms and findings (severity, frequency) of the disease or health condition?

Appropriate shock

In three studies (556 patients), the rate of appropriate shocks was lower in patients with subcutaneous ICDs than in patients with conventional ICDs [6, 7, 9]. However, this difference was not statistically significant in any of the three studies.

For example, the observational study with the longest follow-up [7] showed that adequate shocks were less frequent in patients with subcutaneous ICDs than in patients with transvenous ICD (8.6% [12 of 140] versus 17.1% [24 of 140]. At 5 year, Kaplan-Meier analysis revealed estimated rate of patients with appropriate shocks of 17.0% (95% CI: 6.3–26.4) in the subcutaneous group and 21.3% (95% CI: 12.6-27.3) in the transvenous group. The hazard ratio (HR) adjusted for ICD programming was 0.68 [self-calculated from HR transvenous vs. subcutaneous ICD], p = 0.36) [7].

In two other observational studies [6, 9] with 276 patients, the incidence of adequate shock deliveries was also lower in the subcutaneous ICD group compared to the transvenous ICD group, but difference did not reach statistical significance.

adäquate Schockabgabe: in 3 Studien numerisch weniger bei PatientInnen mit subkutanen ICD als mit transvenösen ICD Unterschiede jedoch statistisch nicht signifikant

z. B.: eine Studie mit 280 PatientInnen: Kaplan-Meier Analyse Adäquate Schockabgabe 5-Jahre: 17,0 % vs. 21,3 % HR 0.68, p = 0,36

Dooo6 – How does the technology affect progression (or recurrence) of the disease or health condition?	
No evidence was found to answer this research question	keine Evidenz vorhanden
Function	
Doo11 – What is the effect of the subcutaneous ICD on patients' body functions?	
No evidence was found to answer this research question.	keine Evidenz vorhanden
Doo16 – How does the use of the subcutaneous ICD affect activities of daily living?	
No evidence was found to answer this research question.	keine Evidenz vorhanden
Health-related quality of life	
Doo12 – What is the effect of the subcutaneous ICD on generic health-related quality of life?	
Two observational studies with 418 patients evaluated the quality of life in patients with subcutaneous ICD and transvenous ICD by administration of the generic 12-item Short-Form Health Survey (SF-12). Physical and mental component summary scores of the SF-12 range on a scale from 0 (poorest possible) to 100 (best possible) [5, 8].	Lebensqualität gemessen mit SF-12: 2 Studien
One study compared the quality of life in patients with subcutaneous ICD from the prospective, multicentre, observational substudy of the EFFORT-LESS S-ICD ¹ registry (n = 167) with a propensity score-matched cohort with transvenous ICD of the single-centre MIDAS study (n = 167) [5]. Multivariable model adjusted for prior selected variables and baseline differences between the two cohorts revealed no statistically significant differences at baseline, 3 months and 6 months between patients with subcutaneous ICDs and transvenous ICDs [5].	Darunter 1 Beobachtungsstudie mit Propensity Score Matching und 334 PatientInnen
The mean physical quality of life scores (standard deviation [SD] self-calculated from 95% CI) were similar at baseline (40.5 \pm 11.8 vs. 40.8 \pm 10.9), 3 months (43.6 vs. 43.9), and 6 months (43.5 \pm 12 vs. 43.7 \pm 11, mean difference [self-calculated] -0.2; 95% CI: -2.67-2.27). In addition, the mean mental quality of life score was not statistically significantly different at baseline (42.4 \pm 11.8 vs. 42.3 \pm 11.0), 3 months (45.9 vs. 45.7) and 6 months (45.2 \pm 12.5 vs. 45.1 \pm 11.6, mean difference [self-calculated] 0.15; 95% CI: -2.44-	Physische und mentale Lebensqualität nach subkutanen und transvenösen ICD ähnlich zu Beginn, nach 3 und 6 Monaten

3 and 6 months [5].

¹ Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD

2.74). Statistically significant improvements in physical and mental quality of life were observed in both groups between the time of implantation and 3 months and between the time of implantation and 6 months, but not between

In a second observational study, 42 patients with subcutaneous ICD were matched to 42 patients with single-chamber transvenous ICD and evaluated with respect to posttraumatic stress disorder, psychological disorders and quality of life [8].Quality of life was assessed after mean duration of 622 days after subcutaneous ICD and 942 days after transvenous implantation. The physical well-being score obtained by the SF-12 questionnaire was statisti-

cally significantly higher with subcutaneous than transvenous ICDs (46.6 \pm 9.9 vs. 39.9 \pm 12.5, mean difference [self-calculated] 6.7; 95% CI: 1.88-11.52). However, the mental well-being score did not statistically significantly differ between groups (51.9 \pm 10.4 vs. 51.8 \pm 10.8, mean difference [self-calculated] 0.10; 95% CI: -4.43 – 4.63) [8].

Doo13 – What is the effect of the subcutaneous ICD on disease-specific quality of life?

keine Evidenz vorhanden No evidence was found to answer this research question.

6 Safety

6.1 Outcomes

The following outcomes were defined as *crucial* to derive a recommendation:

- Inappropriate shocks
- Lead complications
- Infections
- Haematoma
- Pericardial tamponade

Outcomes were selected based on a recently published systematic review [3].

6.2 Included Studies

Five eligible observational studies [4, 6, 7, 9, 10] and one systematic review [3] reported data on harms. Study characteristics were described above and results of included studies are displayed in Table A-1 and the quality of evidence is presented in Table A-4.

5 Beobachtungsstudien und 1 systematischer Review

Kritische Endpunkte zur Sicherheit

6.3 Results

Patient safety

Cooo8 – How safe is the subcutaneous ICD in comparison to the conventional transvenous ICD?

Inappropriate shocks

In four observational studies (N = 738) with a follow-up period ranging from six months to five years, the number of patients with inappropriate shock in the subcutaneous ICD group and the conventional transvenous ICD group were reported [4, 6, 7, 9].

Inappropriate shock was not statistically significantly different between patients with subcutaneous and transvenous ICDs based on a random-effects meta-analysis with four studies [4, 6, 7, 9] and 738 patients (29 of 369 vs. 44 of 369, OR 0.87; 95% CI: 0.51-1.49) [3].

Causes of inappropriate shock delivery differed among groups. Subanalysis of three studies [6, 7, 9] showed that inappropriate therapy due to supraventricular tachycardia was statistically significantly less frequent with subcutaneous ICD (3 of 278 vs. 29 of 278; OR 0.12; 95% CI: 0.04-0.35).

In contrast, statistically significant more inappropriate shocks because of oversensing (sensing of noise, T-wave oversensing) occurred with the subcutaneous ICD [3].

Inadäquate Schockabgabe: 4 Beobachtungsstudien

Meta-Analyse mit 4 Studien und 738 PatientInnen OR 0,87 (95 % KI: 0,51-1,49)

Lead complications

Sonden-Komplikationen: 4 Beobachtungsstudien mit 6.316 PatientInnen

> Meta-Analyse mit 4 Studien: statistisch signifikant weniger Sondenkomplikationenmit subkutanem ICD OR 0,13 (95 % KI: 0,05-0,38)

Four observational studies reported data on lead complications [6, 7, 9, 10]. Three studies showed statistically significantly fewer lead complications with subcutaneous ICD than with transvenous ICD [6, 7, 10]. In the study with the longest observation period of five years, 0.7% (1 of 140) of patients with subcutaneous ICD experienced lead complications, while patients with transvenous (single and dual-chamber) ICD experienced complications in 12.1% of cases (17 of 140) [7]. At 5 year, Kaplan-Meier estimates of patients with lead complications were 0.8% (95% CI: 0-2.2) in the subcutaneous compared to 11.5% (95% CI: 5.3-17.2) (p = 0.03) in the transvenous group.

Meta-analysis of four observational studies (6,316 patients) [6, 7, 9, 10] yielded statistically significantly fewer lead complications in the subcutaneous ICD group compared to the transvenous ICD group (odds ratio [OR] 0.13, 95% CI: 0.05–0.38) [3].

Infections

Infektionen: 5 Beobachtungsstudien mit insgesamt 6.498 PatientInnen Five eligible observational studies reported data on infections. Different definitions of an infection were used in individual studies: infections requiring explantation [4], infections necessitating removal of the ICD system and/ or antibiotic treatment [9], infection requiring revision [6], or any infection [7, 10].

Meta-Analyse mit 5 Studien: kein statistisch signifikanter Unterschied OR 0,75 (95 % KI: 0,30-1,89) All five studies showed no statistically significant difference in the rate of infections between patients with subcutaneous ICDs and patients with conventional transvenous ICDs. In the largest observational study (N = 5,760), infections were rare in all three groups. During the hospital stay, which lasted an average of one day, 0 to 0.1% of the patients had an infection (subcutaneous ICD: 0.05% [1 of 1,920], transvenous single-chamber ICD: 0% [0 of 1,920], transvenous dual-chamber ICD ICD: 0.1% [2 of 1,920]) [10]. In one study with a follow-up to five years, the rate of infections in both groups were similar (Kaplan-Meier estimates 4.1% [95% CI: 0.5-7.7] vs. 3.6% [95% CI: 0.0-7.1], p = 0.36) [7].

Random-effects meta-analysis (5 studies 6,498 patients) [4, 6, 7, 9, 10] support findings of individual studies, with no statistically significant difference of risk for infections between the subcutaneous ICD group compared with the transvenous ICD group (8 of 2,269 vs. 13 vs. 4,189; OR 0.75, 95% CI: 0.30-1.89) [3].

Haematoma

Hämatome: 3 Studien selten in beiden Gruppen Overall, haematomas were rare (subcutaneous ICD: 9 of 2,080 vs. 3 of 4,000). Both a larger study (N = 5,760) [10] (subcutaneous ICD vs. dual-chamber transvenous ICD: RR 3.5, 95% CI: 0.7-19.8) and two smaller retrospective observational studies (N = 320) [4, 6] found no statistically significant difference between subcutaneous ICDs and transvenous single- or dual-chamber ICDs.

Pericardial tamponade

Two studies (N = 5,898) reported the rate of pericardial tamponade [9, 10]. In the largest study involving 5,760 patients, no pericardial tamponades occurred during hospital stay in the group with subcutaneous ICDs and the single-chamber ICD group. However, in the dual-chamber ICD group, five pericardial tamponades were observed [10].

Cooo4 – How does the frequency or severity of harms change over time or in different settings?

No evidence was found to answer this research question

Cooo5 – What are the susceptible patient groups that are more likely to be harmed through the use of the subcutaneous ICD?

No evidence was found to answer this research question

Cooo7 – Are the subcutaneous ICD and transvenous ICD associated with user-dependent harms?

No evidence was found to answer this research question

Größte Studie: Implantation des subkutanen und transvenösen Einkammer-ICD keine Perikardtamponade, 5 bei Implantation eines Zweikammer-ICD

keine Evidenz zu den Endpunkten Schweregrad, sensible PatientInnengruppen

und anwenderabhängige Schäden vorhanden

7 Quality of evidence

The quality of evidence was rated according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) scheme [16] for each endpoint individually. Each study was rated by two independent researchers. In case of disagreement, a third researcher was involved to resolve the difference. A more detailed list of criteria applied can be found in the recommendations of the GRADE Working Group [16].

GRADE uses four categories to rank the quality of evidence:

- High = We are very confident that the true effect lies close to that of the estimate of the effect;
- Moderate = We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different;
- Low = Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect;
- Very low = Evidence either is unavailable or does not permit a conclusion.

The ranking according to the GRADE scheme for the research question can be found in the summary of findings table below and in the evidence profile in Appendix Table A-4.

The quality of evidence for the effectiveness and safety of subcutaneous ICD in comparison to transvenous ICD is very low for all outcomes.

Risk of Bias of included observational studies was assessed with the Newcastle-Ottawa Scale [11] and is presented in Table A-2 in the Appendix. Three studies were considered as high [4, 6, 8] and four as medium risk of bias [5, 7, 9, 10]. Main reasons for downgrading refer to selection of control group, comparability of cohorts and follow-up duration.

The only systematic review was rated as medium risk of bias, since assessment with the AMSTAR-2 checklist [12] revealed moderate overall confidence in the results of the review (see Table A-3).

Qualität der Evidenz nach GRADE

Qualität der Evidenz ist sehr niedrig

Bias Risiko ist hoch für 3 und mittel für 4 Beobachtungsstudien

Outcomes	Anticipated absolute effects* (95% CI)				Certainty of	
	Risk with transvenous ICD	Risk with subcutaneous ICD	Relative effect (95% Cl)	№ of participants (studies)	the evidence (GRADE)	Comments
Mortality (In-hospital) [10]	1 per 1.000	2 per 1.000 (0 to 8)	RR 2.0 (0.4 to 9.9)	5760 (1 observational study)	⊕OOO VERY LOW ^a	
Mortality (up to 6 months) [4]	22 per 1.000	22 per 1.000 (3 to 153)	RR 1.00 (0.14 to 6.95)	182 (1 observational study)	€ VERY LOW ^{b,c,d}	
Mortality (up to 5 years) [7]	43 per 1.000	o per 1.000 (o to o)	not estimable	280 (1 observational study)	⊕OOO VERY LOW ^{c,d}	
Appropriate shock/therapy (7.1 months) [6]	130 per 1.000	43 per 1.000 (12 to 154)	RR 0.33 (0.09 to 1.18)	138 (1 observational study)	€ VERY LOW ^{b,c,d}	
Appropriate shock/therapy (2.6 years) [9]	72 per 1.000	43 per 1.000 (11 to 155)	RR 0.60 (0.15 to 2.14)	138 (1 observational study)	⊕OOO VERY LOW ^{c,d}	
Appropriate shock/therapy (up to 5 years) [7]	171 per 1.000	120 per 1.000 (0 to 0)	HR 0.68	280 (1 observational study)	⊕OOO VERY LOW ^d	
Inappropriate shocks [3] pooled Data of [4, 6, 7, 9]	95 per 1.000	83 per 1.000 (51 to 135)	OR 0.87 (0.51 to 1.49)	738 (4 observational studies)	⊕OOO VERY LOW ^{a,b}	
Lead complications [3] pooled Data of [6, 7, 9, 10]	10 per 1.000	1 per 1.000 (1 to 4)	OR 0.13 (0.05 to 0.38)	6316 (4 observational studies)	⊕OOO VERY LOW ^e	
Infections [3] pooled Data of [4, 6, 7, 9, 10]	3 per 1.000	2 per 1.000 (1 to 6)	OR 0.75 (0.30 to 1.89)	6498 (5 observational studies)	⊕OOO VERY LOW ^b	
Pericardial tamponade [9, 10]	2 per 1.000	o per 1.000 (0 to 1)	RR ranged from 0.18 to 0.33	5898 (2 observational studies)	€ VERY LOW ^c	
Haematoma [4, 6, 10]	1 per 1.000	o per 1.000 (2 to 3)	RR ranged from 3.0 to 3.5	6080 (3 observational studies)	€ VERY LOW ^{b,c}	
Quality of life – physical well-being score [8] assessed with: 12-item Short-Form Health Survey (SF-12)		The mean quality of life – physical well- being score [8] in the intervention group was 6.7 higher (1.88 higher to 11.52 higher)	-	84 (1 observational study)	€OOO VERY LOW ^{b,d}	
Quality of life – physical well-being score [5] assessed with: 12-item Short-Form Health Survey (SF-12)		The mean quality of life – physical well- being score [5] in the intervention group was 0.2 lower (2.67 lower to 2.27 higher)	-	334 (1 observational study)	€OOO VERY LOW ^d	
Quality of life – mental well-being score [8] assessed with: 12-item Short-Form Health Survey (SF-12)		The mean quality of life – mental well- being score [8] in the intervention group was 0.1 higher (4.43 lower to 4.63 higher)	-	84 (1 observational study)	€OOO VERY LOW ^{b,d}	
Quality of life – mental well-being score [5] assessed with: 12-item Short-Form Health Survey (SF-12)		The mean quality of life – mental well- being score [5] in the intervention group was 0.15 higher (2.44 lower to 2.74 higher)	-	334 (1 observational study)	€OOO VERY LOW ^{d,f}	

Table 7-1: Summary of findings table of subcutaneous ICD compared with transvenous ICD in patients at high risk of sudden cardiac death

Explanations: *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

^c Small number of events

Abbreviations: CI = Confidence interval; RR = Risk ratio; HR = Hazard Ratio; OR = Odds ratio; MD = Mean difference

^a Effect estimates includes appreciable benefit and harms

^b Two studies with high risk of bias [4, 6]

- ^d Sample size does not meet optimal information size.
- ^e Studies with high or medium risk of bias
- ^f Medium risk of bias

LBI-HTA 2018

8 Discussion

Based on the available evidence of seven observational studies [4-10] and one systematic review [3], comparing patients receiving subcutaneous ICDs or transvenous ICDs, no statistically significant differences were observed in terms of overall mortality, rate of adequate and inadequate shocks, infections, and haematomas. Some of these results, however, have wide confidence intervals and encompass differences that would be clinically relevant.

Lead complications were statistically significantly less frequent in patients with subcutaneous ICDs as compared to transvenous ICDs. Difference regarding lead complications, however, are expected by the nature of these devices, as subcutaneous ICDs have no contact with cardiac structures due to the absence of transvenous lead implantation.

The quality of evidence of all outcomes is very low due to risk of bias and imprecision, indicating substantial uncertainty about these findings.

When interpreting the results of our evidence summary, several limitations related to risk of bias and to study design have to be considered:

First, the follow-up period varied considerably among individual studies ranging from the duration of the hospital stay to five years after ICD implantation. Therefore, most of the studies do not reflect long-term complications. Due to this limitation, pooled results from random-effects meta-analysis are limited.

Second, in few studies, despite matching, there were still differences of baseline characterises between patients who received subcutaneous ICDs and patients who had a conventional transvenous ICDs implanted. In particular, differences in patient characteristics may have influenced outcomes. It should be emphasized that not all studies clearly stated that they excluded patients with an indication for a pacemaker, anti-tachycardia pacing or cardiac resynchronization therapy from the control group with transvenous ICD. Therefore, unevenly distributed prognostic factors could have influenced the outcomes.

Third, due to the small sample size (ranging from 138 to 334 patients), power of most of the studies is low to detect differences. However, this was overcome by the meta-analysis of the included systematic review.

Finally, the most important limitation is that for most effectiveness and safety endpoints, only few events occurred, limiting precision of the findings. Most of the non-significant results are generally indeterminate. The confidence intervals are wide and include important differences.

Applicability of included studies is summarized in Table A-5.

Our review focused on comparative effectiveness and safety of the subcutaneous and transvenous ICD. For that reason, findings of two large cohort studies without control group, the IDE (Investigational Device Exemption) study [29, 30] and the EFFORTLESS (Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD) study [30, 31] are not included in this review. Resultate für Wirksamkeit: nicht signifikater Unterschied

Resultate für Sicherheit: weniger Sondenkomplikationen bei subkutanem ICD

Qualität der Evidenz: sehr niedrig

Bias Risiko und andere Limitationen

unterschiedliche Beobachtungszeiträume der Studien von Krankenhausaufenthalt bis zu 5 Jahren

trotz Matching Baseline Patientencharakteristika unterschiedlich in manchen Studien

bei einigen Endpunkten nur wenige Ereignisse → breite KI die relevante Unterschiede einschließen können laufender RCT PRAETORIAN trial

Subkutaner vs. Transvenöser ICD geplante Anzahl an Studienteilnehmern: 850 Patienten

Voraussichtliches Ende: Dezember 2019 Our searches yielded the study protocol of an investigator-initiated, multicentre, randomized controlled PRAETORIAN (Prospective, RAndomizEd comparison of subcutaneous and tRansvenous ImplANtable cardioverter-defibrillator therapy) trial [13]. Planned sample size of this study is 850 patients with an indication for ICD therapy and without an indication for pacing, randomized to either the subcutaneous or transvenous ICD (1:1) [14]. This study is adequately powered to claim non-inferiority and/or superiority of the subcutaneous ICD regarding a composite primary endpoint of inappropriate shocks and ICD-related complications (within 48 months). According to the ClinicalTrials.gov (NCT01296022) entry, estimated completion date is December 2019 [14]. Thus, no results are available yet.

In addition, we found the ongoing randomized controlled ATLAS (Avoid Transvenous Leads in Appropriate Subjects) S-ICD trial (ClinicalTrials.gov, NCT02881255). Details of this trial are provided in Table A-6.

Conclusion

Evidenz derzeit unzureichend für den Vergleich der Wirksamkeit, jedoch deutlich geringeres Risiko für Sondenkomplikationen mit subkutanem ICD The results from seven observational studies and one systematic review are inadequate to draw conclusions about the comparative effectiveness of subcutaneous and transvenous ICDs.

These studies, however, indicate substantially lower risk for lead complications in patients with subcutaneous ICD.

The ongoing randomized controlled PRAETORIAN study will provide more reliable results to answer this question.

9 Recommendation

In Table 9-1 the scheme for recommendations is displayed and the according choice is highlighted.

Table 9-1: Evidence based recommendations

		The inclusion in the catalogue of benefits is recommended .
>	×	The inclusion in the catalogue of benefits is recommended with restrictions .
		The inclusion in the catalogue of benefits is <i>currently</i> not recommended.
		The inclusion in the catalogue of benefits is not recommended .

Reasoning:

The current evidence is not sufficient to determine whether the subcutaneous ICD is equally or more effective than the transvenous ICD. Based on the available evidence no statistically significant differences were observed in terms of overall mortality, rate of adequate and inadequate shocks, infections, and haematomas. However, lead complications were statistically significantly less frequent in patients with subcutaneous ICDs as compared to transvenous ICDs. Thus, inclusion in the benefit catalogue is recommended with restrictions.

New study results will potentially influence the effect estimate considerably. The re-evaluation is recommended in year 2020 when results of an ongoing randomized controlled trial are published.

Resultate für Sicherheit: weniger Sondenkomplikationen bei subkutanem ICD; Resultate für Wirksamkeit: kein statistisch signifikanter Unterschied

Ergebnisse eines RCTs werden erwartet

10 References

- Mehra R: Global public health problem of sudden cardiac death. J Electrocardiol 2007, 40(6 Suppl):S118-122.
- [2] Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death, Interventional procedures guidance [IPG603]. [Accessed 12 February 2018] Available from: https://www.nice.org.uk/guidance/ipg603.
- [3] Basu-Ray I, Liu J, Jia X, Gold M, Ellenbogen K, DiNicolantonio J, Komócsi A, Vorobcsuk A, Kim J, Afshar H et al: Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. A Meta-Analysis of Case-Control Studies. JACC: Clinical Electrophysiology 2017.
- [4] Mithani AA, Kath H, Hunter K, Andriulli J, Ortman M, Field J, Russo AM: Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. Europace : European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2017.
- [5] Pedersen SS, Mastenbroek MH, Carter N, Barr C, Neuzil P, Scholten M, Lambiase PD, Boersma L, Johansen JB, Theuns DA: A Comparison of the Quality of Life of Patients With an Entirely Subcutaneous Implantable Defibrillator System Versus a Transvenous System (from the EFFORTLESS S-ICD Quality of Life Substudy). *The American journal of cardiology* 2016, 118(4):520-526.
- [6] Kobe J, Reinke F, Meyer C, Shin DI, Martens E, Kaab S, Loher A, Amler S, Lichtenberg A, Winter J et al: Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverterdefibrillators: a multicenter case-control study. *Heart rhythm* 2013, 10(1):29-36.
- [7] Brouwer TF, Yilmaz D, Lindeboom R, Buiten MS, Olde Nordkamp LR, Schalij MJ, Wilde AA, van Erven L, Knops RE: Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. *Journal of the American College of Cardiology* 2016, 68(19):2047-2055.
- [8] Kobe J, Hucklenbroich K, Geisendorfer N, Bettin M, Frommeyer G, Reinke F, Dechering D, Burgmer M, Eckardt L: Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. *Clinical research in cardiology : official journal of the German Cardiac Society* 2017, 106(5):317-321.
- [9] Honarbakhsh S, Providencia R, Srinivasan N, Ahsan S, Lowe M, Rowland E, Hunter RJ, Finlay M, Segal O, Earley MJ et al: A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. *International journal of cardiology* 2017, 228:280-285.
- [10] Friedman DJ, Parzynski CS, Varosy PD, Prutkin JM, Patton KK, Mithani A, Russo AM, Curtis JP, Al-Khatib SM: Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. *JAMA cardiology* 2016, 1(8):900-911.
- [11] Wells G SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Accessed 12 February 2018] Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- [12] Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E et al: AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ (Clinical research ed) 2017, 358:j4008.
- [13] Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, Delnoy PP, van Dessel PF, Driessen AH, de Groot JR *et al*: Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. *American heart journal* 2012, 163(5):753-760.e752.

- [14] Amsterdam AMC-Uv, Corporation BS: A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy. [Accessed 12 February 2018] Available from: https://ClinicalTrials.gov/show/NCT01296022.
- [15] Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G et al: 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European heart journal 2015, 36(41):2793-2867.
- [16] Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H et al: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology* 2011, 64(4):383-394.
- [17] Al-Khatib SM, Stevenson WG, Ackerman MJ, Gillis AM, Bryant WJ, Hlatky MA, Callans DJ, Granger CB, Curtis AB, Hammill SC et al: 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Heart rhythm* 2017.
- [18] Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT et al: An Entirely Subcutaneous Implantable Cardioverter–Defibrillator. New England Journal of Medicine 2010, 363(1):36-44.
- [19] Lewis GF, Gold MR: Safety and Efficacy of the Subcutaneous Implantable Defibrillator. *Journal of the American College of Cardiology* 2016, 67(4):445-454.
- [20] DiMarco JP: Implantable cardioverter-defibrillators. The New England journal of medicine 2003, 349(19):1836-1847.
- [21] Mirowski M, Reid PR, Mower MM, Watkins L, Gott VL, Schauble JF, Langer A, Heilman MS, Kolenik SA, Fischell RE et al: Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. The New England journal of medicine 1980, 303(6):322-324.
- [22] A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *The New England journal of medicine* 1997, 337(22):1576-1583.
- [23] Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D et al: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. The New England journal of medicine 1996, 335(26):1933-1940.
- [24] Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML: Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infarction and Reduced Ejection Fraction. New England Journal of Medicine 2002, 346(12):877-883.
- [25] Akerström F, Arias MA, Pachón M, Puchol A, Jiménez-López J: Subcutaneous implantable defibrillator: State-of-the art 2013. World journal of cardiology 2013, 5(9):347-354.
- [26] Maria ED, Olaru A, Cappelli S: The Entirely Subcutaneous Defibrillator (S-Icd): State of the Art and Selection of the Ideal Candidate. *Current cardiology reviews* 2015, 11(2):180-186.
- [27] Raatikainen MJ, Arnar DO, Zeppenfeld K, Merino JL, Levya F, Hindriks G, Kuck KH: Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2015, 17 Suppl 1:i1-75.
- [28] Chue CD, Kwok CS, Wong CW, Patwala A, Barker D, Zaidi A, Mamas MA, Cunnington C, Ahmed FZ: Efficacy and safety of the subcutaneous implantable cardioverter defibrillator: a systematic review. *Heart (British Cardiac Society)* 2017, 103(17):1315-1322.

- [29] Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, Rashtian M, Kremers M, Crozier I, Lee KL et al: Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. *Circulation* 2013, 128(9):944-953.
- [30] Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, Scholten M, Hood M, Kuschyk J, Jones P et al: Implant and Midterm Outcomes of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. *Journal of the American College of Cardiology* 2017, 70(7):830-841.
- [31] Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, Knops RE, Weiss R, Leon AR, Herre JM et al: Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. *Journal of the American College of* Cardiology 2015, 65(16):1605-1615.

Evidence tables of individual studies included for clinical effectiveness and safety

Table A-1: Subcutaneous versus transvenous	s ICD: Results from observational studies
--	---

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Country	Germany	Netherlands	Unites States of America	Czech Republic, Denmark, Germany, Italy, the Netherlands, New Zealand, Portugal, and the United Kingdom	Germany	England	Unites States of America
Sponsor	-	-	Supported by the American College of Cardiology's National Cardiovascular Data Registry (NCDR)	Cameron Health Inc.	-	-	-
Intervention	Subcutaneous ICD	Subcutaneous ICD	Subcutaneous ICD	Subcutaneous ICD	Subcutaneous ICD	Subcutaneous ICD	Subcutaneous ICS
Comparator	Single-chamber transvenous ICD	Single-chamber and dual-chamber transvenous ICD	Single-chamber and dual chamber transvenous ICD	Single-chamber and dual-chamber transvenous ICD	Single-chamber transvenous ICD	Single- and dual-chamber transvenous ICD	Single-chamber transvenous ICD
Study design	Observational study Control matched by sex and age (±5 years)	Observational study with propensity score matching	Observational study with propensity score matching	Observational study with propensity score matching	Observational study Control matched by sex and age (±5 years)	Retrospective observational study with propensity score matching	Observational study Control matched by age, sex and dialysis status
Number of patients, total and intervention vs. comparator	138 69 vs. 69	280 140 VS. 140	5760 1920 vs. 1920 vs. 1920	334 167 vs. 167	84 42 V5. 42	138 69 vs. 69	182 91 vs. 91

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Inclusion criteria	Indication for ICD implantation according to ACA/AHA and ESC guidelines for primary and secondary prevention, no indication for stimulation or slow ventricular tachycardias (VTs). Implantation at the University Hospitals of Düsseldorf, Munich and Münster, Germany	Patients implanted with single- and dual-chamber TV- ICDs between 2005 and 2014 at the Leiden University Medical Center (LUMC), and patients implanted with S-ICDs between 2009 and 2015 at the Academic Medical Center (AMC)	All Patients admitted for ICD implantation (September 28, 2012-March 31, 2015) and eligible for an S-ICD, SC TV-ICD or DC TV-ICD	Patients implanted with a first generation S-ICD system due to a primary or secondary prevention indication according to local clinical guidelines The intervention cohort (EFFORTLES S-ICD QoL substudy) included prospective and first time implant patients from 29 sites (Czech Republic, Denmark, Germany, Italy, Netherlands, New Zealand, Portugal, United Kingdom) from March 2011 to July 2014. Comparison cohort were patients from the MIDAS study recruited at the Erasmus Medical Center in Rotterdam, Netherlands from August 2003 to February 2010.	Hospital München, Germany and attended the outpatient clinic regularly for device follow-up.	Indication for ICD implantation for primary and secondary prevention. Patients implanted with subcutaneous ICD between 2010 and 2015 in a single tertiary centre, patients implanted a transvenous ICD over a contemporary time in the same centre (Barts Heart Center, London)	All patients who had a subcutaneous ICDs implanted between October 22, 2012 and September 22, 2015 at the Cooper University Hospital, Camden, USA. Ninety-one patients who received subcutaneous ICD were consecutively identified and they were then matched to single.chamber transvenous ICD patients during this time frame.
Exclusion criteria	NR	Patients included in the PRAETORIAN trial	Patients with previous ICD, bradycardia or resynchronization indication for permanent pacing Patients under- going ICD implantation during an acute hospitalization	Patients participating in another study that was considered to interfere with interpretation of the results from the EFFORT- LESS S-ICD Registry, had previously been implanted with an ICD, experienced incessant VT and/or spontaneously, frequently recurring VT, or if they had a bradycardia indication or cardiac resynchronization therapy	NR	Patients who had a concomitant pacing indication, biventricular devices, documentation of sustained mono- morphic ventricular tachycardia (VT) likely to require anti- tachycardia pacing (ATP), and advisory transvenous leads	Dual-chamber transvenous ICD, Cardiac resynchronization therapy (CRT)
Age of patients, yrs	Mean ± SD: 45.7 ± 15.7 vs. 47.7 ± 14.7, p = 0.433	Median (inter- quartile range): 41 (26-52) vs. 42 (32-50), P = 0.33	Mean ± SD: 54.0 (15.1) vs. 53.7 (15.2) vs. 54.1 (15.0), p = NR	Mean ± SD: 54 ± 16 vs. 55 ± 13, p = 0.8831	Mean ± SD: 44.6 ± 12.5 vs. 44.7 ± 12.1, P = 0.96	Mean ± SD: 35 ± 13 vs. 40 ± 10, p = 0.17	Mean ± SD: 54.93 ± 13.61 Vs 56.30 ± 12.71, P = 0.017
Female n (%)	19 (27.5) VS. 19 (27.5), p = 1.0	56 (40) vs. 53 (38), p = 0.71	627 (32.7) vs. 598 (31.2) vs. 633 (33), p = NR	45 (27%) vs 47 (28%) p = 0.8065	12 (28.6) vs. 12 (28.6), p = 1.0	17 (25) vs. 17 (25), p = 1.00	40 (44) VS. 41 (55) P = 1.0

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Primary prevention n (%)	41 (59.4) vs. 34 (50.0), p = 0.268	93 (66) vs. 86 (61), p = 0.38	NR	123 (74) vs. 115 (69), P = 0.3334	26 (61.9) vs. 23 (54.8), p = 0.66	56 (81) vs. 56 (81), p = 1.0	74 (81.3) vs. 70 (76.9), p = 0.585
First ICD implantation n (%)	53 (76.8) vs. NR, p = NR	121 (86) vs. 125 (89), p = 0.47	1920 (100) vs. 1920 (100) vs. 1920 (100)	167 (100) vs. 167 (100)	NR	NR	NR
LVEF, %	Mean ± SD: 46.2 ± 15.6 vs. 40.6 ± 15.9, p = 0.084	Median: 50 vs. 49 P = 0.91	Mean ± SD: 31.2 ± 13.7 vs. 31.4 ± 13.8 vs. 31.2 ± 13.9, p = NR	NR	Mean ± SD: 49.0 ± 13.7 vs. 44.8 ±16.6 p = 0.28	Mean ± SD: 57 ± 15 vs. 58 ±13, p = 0.80	Mean ± SD 26.79 ± 12.08 vs. 27.78 ± 11.66, P = 0.534
Atrial fibrillation or Atrial flutter n (%)		13 (9) VS. 21 (15), P = 0.14	322 (16.8) vs. 323 (16.8) vs. 370 (19.3), p = NR	36 (22) vs. 30 (18), p = 0.4097	NR	NR	14 (15.4) Vs. 15 (16.5), p = 1.00
lschemic heart disease or Coronary artery disease n (%)	11 (15.9) vs. 13 (18.8), p = 0.653	NR	879 (45.8) vs. 890 (46.4) vs. 857 (44.6), p = NR	NR	3 (7.1) vs. 6 (14.3) p = 0.48	NR	NR
Ischemic cardio- myopathy n (%)	NR	26 (19) vs. 41 (29), p = NR	NR	12 (7) vs. 12 (7), p = 1.00	NR	6 (9) vs. 5 (7), p = 1.0	NR
Nonischemic cardiomyopathy n (%)	NR	28 (20) vs. 30 (21), p = NR	846 (44.1) vs. 832 (43.3) vs. 845 (44), P = NR	NR	NR	NR	57 (62.6) vs. 51 (56), p = 0.451
Dilated cardio- myopathy n (%)	25 (36.2) vs. 32 (46.4), p = 0.226	NR	846 (44.1) vs. 832 (43.3) vs. 845 (44), p = NR	25 (15) vs. 39 (23), p = 0.0516	7 (16.7) vs. 12 (28.6), p = 0.30	4 (6) vs. 5 (7), p = 1.0	NR
Hyperthrophic cardiomyopathy n (%)	10 (14.5) vs. 4 (5.8), p = 0.091	NR	123 (6.4) vs. 122 (6.4) vs. 120 (6.3), p = NR	22 (13) VS. 18 (11), p = 0.5002	10 (23.8) VS. 3 (7.1), p = 0.07	41 (59) vs. 42 (61), p = 1.0	NR
Congenital heart disease n (%)	3 (4.4) vs. 3 (4.4), p = 1.0	5 (4) vs. 12 (9), p = NR	Ebstein anomaly: 3 (0.2) vs. 1 (0.1) vs. 1 (0.1) Transposition of the great vessels: (0.2) vs. 2 (0.1) vs. 1 (0.1) Tetralogy of Fallot 6 (0.3) vs. 5 (0.3) vs. 9 (0.5) Arrhythmogenic right ventricular dysplasia: 11 (0.6) vs. 11 (0.6) vs. 6 (0.3) Common ventricle: 2 (0.1) vs. 0 vs. 0	NR	4 (9.5) vs. 5 (11.9), p = 1.0	1 (1) vs. 1(1), p = 1.0	NR

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Electrical heart disease or Syndromes associated with sudden cardiac death or Genetic arrhythmia syndrome n (%)	Electrical heart disease: 14 (20.3) vs. 2 (2.9), p = 0.002	Genetic arrhythmia syndrome: 75 (54) vs. 54 (39), p = NR	Syndromes associated with sudden cardiac death: Long QT syndrome: 66 (3.4) vs. 41 (2.1) vs. 77 (4) Short QT syndrome: 1 (0.1) vs. 0 vs. 1 (0.1) Brugada syndrome: 21 (1.1) vs. 28 (1.5) vs. 6 (0.3) Catecholeminergic polymorphic VT: 1 (0.1) vs. 3 (0.2) vs. 3 (0.2) Idiopathic VF: 17 (0.9) vs. 14 (0.7) vs. 18 (0.9)	NR	Electrical heart disease: 7 (16.7) vs. 2 (4.8), p = 0.16	Arrhythmogenic right ventricular cardiomyopathy: 7 (10) vs. 6 (9), p = 0.79 Idiopathic ventricular fibrillation: 6 (9) vs. 6 (9), p = 1.0 Brugada Syndrome: 4 (6) vs. 4 (6), p = 1.0	NR
Follow-up (months)	Mean ± SD: 7.1 ± 4.5 months Max: 24 months	Median: 36 vs. 60 months, p < 0.001 Max: 50 months	Max: In-hospital	Max: 6 months	Time since ICD implantation Mean ± SD: Subcutaneous ICD: 20.7 ± 10.6 months Single-chamber ICD: 31.4 ± 10.4 7 months	Mean ± SD: Subcutaneous ICD: 31 ±19 months Transvenous ICD: 32± 21 months Max: 60 months	Max: 6 months
Loss to follow-up, n (%)	1 (1.4)	NR	0	0	NR	-	-
	•		C	Dutcome	1		
			Eff	ectiveness			
All-cause mortality n (%)	Mean 7.1 months: Subcutaneous ICD: 1/69 (1.4) vs. Single-chamber ICD: 1/69 (1.4), p = NR	5 years: Subcutaneous ICD: 2/140 (1.4) vs. Single/dual-chamber ICD: 6/140/4.6) Kaplan-Meier analysis for survival: 96% vs. 94,8%, p = 0.42	In-Hospital: Subcutaneous ICD: 3/1920 (0.2) vs. Single- chamber ICD: 2/1920 (0.1) p > 0.99 Subcutaneous ICD: 3/1920 (0.2) vs. Dual-chamber ICD: 1/1920 (0.05), p = 0.64	NR	NR	Mean 2.6 years: Subctanous ICD: o/69 (o) vs. Single-/dual-chamber ICD: o/69 (o)	6 months: Subcutaneous ICD: 2/91 (2.2) vs. Single-chamber ICD: 2/91 (2.2) p = NR

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Appropriate shocks n (%)	Mean 7.1. months: Subcutaneous ICD: 3/69 (4.3) vs. Single-chamber ICD: 9/69 (13.0), p = 0.05	5 years: Subcutaneous ICD: 12/140 (8.6) vs. Single/dual-chamber ICD: 24/140 (17.2) Kaplan-Meier analysis: 17,0% (95% CI: 6.3–26.4) vs.21,3% (95% CI: 12.6–27.3) Single/dual-chamber ICD: HR with adjustment for ICD programming: 1.46; p = 0,36	NR	NR	Subcutaneous ICD: 1/42 (2.4) VS. Single-chamber ICD: 7/42 (16.7) p = 0.06	Mean 2.6 years: Subcutaneous ICD: 3/69 (4.3) vs. Single-/ dual-chamber ICD: 5/69 (7.2), p = NR	6 months: Subcutaneous ICD: 1/91 (1,1) vs. Single- chamber ICD: 0/91 (0), p = NR
Quality of life	NR	NR	NR	12-Item Short-Form Health Survey (SF-12) o = poorest possible, 100 = best possible Physical QoL: ^a Mean (95% Cl): Baseline: 40.48 (38.69-42.27) vs. 40.77 (39.12-42.42), p = 0.8157 3 months: 43.56 (41.79-45.34) vs. 43.85 (42.22-45.48), p = 0.8157 6 months: 43.45 (41.63-45.26) vs. 43.74 (42.06-45.41), p = 0.8157 Mental QoL: ^a Mean (95% Cl): Baseline: 42.39 (40.60-44.19) vs. 42.25 (40.59-43.92), p = 0.9080 3 months: 45.86 (44.04-47.68) vs. 45.72 (44.04-47.40), p = 0.9080 6 months: 45.19 (43.29-47.09) vs. 45.05 (43.28-46.81), p = 0.9080	12-Item Short-Form Health Survey(SF-12) 0 = poorest possible 100 = best possible Physical QoL: Mean ± SD: Baseline: NR Follow-up: 46.6 ± 9.9 VS. 39.9 ± 12.5, p = 0.01 Mental QoL: Mean ± SD: Baseline: NR Follow-up: 51.9 ± 10.4 VS. 51.8 ± 10.8, p = 0.95	NR	NR

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
				Safety			
Inappropriate shocks n (%)	Mean 7.1. months: Subcutaneous ICD: 5/69 (7.2) vs. Single chamber ICD: 3/69 (4.3) p = NR	5 years: Subcutaneous ICD: 20/140 (14.3) vs. Single/dual-chamber ICD: 22/140 (15.7) Kaplan-Meier analysis: 20.5% (95% CI: 11.5-28.6) vs. 19.1% (95% CI: 11.6-26.0) Single-/dual-chamber ICD HR with adjustment for ICD programming: 0.85, P = 0.64	NR	NR	NR	Mean 2.6 years: Subcutaneous ICD: 3/69 (4.3) vs. Single-/ dual-chamber ICD: 6/69 (8.7), p = 0.49	6 months: Subcutanous ICD: 1/91 (1.1) vs. Single-chamber ICD: 2/91 (2.2), p = NR
Lead complications n (%)	Mean 7.1. months: ^b Subcutaneous ICD: 0/69 (0) vs. Single chamber ICD: 2/69 (2.9) p = NR	5 years: Subcutaneous ICD: 1/140 (0.7) vs. Single-/dual- chamber ICD: 17/140 (12.1) Kaplan-Meier analysis: 0.8% (05% CI: 0.0-2.2) vs. 11.5% (95% CI: 5.3-17.2), p = 0.03	In-Hospital: Subcutaneous ICD: 2/1920 (0.1) vs. Single-chamber ICD: 4/1920 (0.2), P = NR Subcutaneous ICD: 2/1920 (0.1) vs. Dual-chamber ICD: 12/1920 (0.6), p = NR	NR	NR	Mean 2.6 years: ^d Subcutaneous ICD: o/69 (o) vs. Single- /dual-chamber ICD: 6/69 (8.7), p = 0.028	NR
Infections n (%)	Mean 7.1. months: ^e Subcutaneous ICD: 1/69 (1.4) vs. Single-chamber ICD: 1/69 (1.4), p = NR	5 years: Subcutaneous ICD: 5/140 (3.6) vs. Single-/dual- chamber ICD: 4/140 (2.9) Kaplan-Meier analysis: 4.1% (95% CI 0.5- 7.7) vs. 3.6% (95% CI: 0.0-7.1), p = 0.36	In-Hospital: Subcutaneous ICD: 1/1920 (0.05) vs. Single- chamber ICD: 0/1920 (0), p = NR Subcutaneous ICD: 1/1920 (0.05) vs. Dual-chamber ICD: 2/1920 (0.1), p = NR	NR	NR	Mean 2.6 years: ^f Subcutaneous ICD: 1/69 (1.4) vs. Single-/dual-chamber ICD: 4/69 (5.8) p = 0.37	6 months: ⁹ Subcutaneous ICD: 3/91 (3.3) vs. single- chamber ICD: 1/91 (1.1), p = NR

Author, year	Köbe, 2013 [6]	Brouwer, 2016 [7]	Friedmann, 2016 [10]	Pedersen, 2016 [5]	Köbe, 2017 [8]	Honoarbakhsh, 2017 [9]	Mithani, 2017 [4]
Haematoma n (%)	Mean 7.1. months: ^h Subcutaneous ICD: 1/69 (1.4) vs. Single-chamber ICD: 0/69 (0) p = NR	NR	In-Hospital: Subcutaneous ICD: 7/1920 (0.4) vs. Single-chamber ICD: 1/1920 (0.05), p = 0.07 Subcutaneous ICD: 7/1920 (0.4) vs. Dual-Chamber ICD: 2/1920 (0.1), p = 0.18	NR	NR	NR	6 months: Subcutaneous ICD: 1/91 (1.1) vs. Single-chamber ICD: 0/91 (0), p = NR
Pericardial tamponade n (%)	NR	NR	In-Hospital: Subcutaneous ICD: o/1920 (0) vs. Single- chamber ICD: o/1920(0), p = NR Subcutaneous ICD: o/1920 (0) vs. Dual- chamber ICD 5/1920 (0.3), p = NR	NR	NR	<30 days: Subcutaneous ICD: 0/60 (0) vs. Single-/dual-chamber ICD: 1/69 (1.4), p = 1.0	NR

Abbreviations: AHA = American Heart Association, ACC = American College of Cardiology, ATP = antitachycardia pacing, HR = Hazard ratio, ICD = implantable cardioverter-defibrillator, ESC = European Society of Cardiology, LVEF = Left ventricular ejection fraction, pts = Patients, NR = not reported, VF = ventricular fibrillation, VT = ventricular tachycardia, TV = transvenous, SC = single chamber, S-ICD = Subcutaneous ICD, PRAETORIAN = Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy) trial, QoL = Quality of life, CI = Confidence Interval, CRT = Cardiac Resynchronization Therapy, TV-ICD = Transvenous ICD, SF-12 = 12-Item Short Form Health Survey,

Explanations:

- ^a Adjusted for confounders
- ^b Reported as lead revision
- ^c Reported as lead dislodgement
- ^d Reported as lead-related complications resulting in lead intervention
- ^e Reported as infection requiring revision
- ^f Reported as device infection
- ^g Reported as infection requiring explant
- ^h Reported as Haematoma requiring revision
- ^{*i*} Reported as Haematoma requiring intervention

⁸ Risk of bias tables and GRADE evidence profile

Internal validity of the included studies was judged by two independent researchers. In case of disagreement, a third researcher was involved to solve the differences.

		2	selection		Comparability				
Study Author, Year	Representative ness of the exposed cohort	Selection of the non exposed cohort	Ascertain- ment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of cohorts on the basis of the design or analysis		Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	Overall Risk of Bias
Köbe, 2013 [6]	1	1	1	1	0	1	1	0	High
Brouwer, 2016, [7]	1	0	1	1	2	1	1	0	Medium
Friedman, 2016, [10]	1	0	1	1	2	1	0	1	Medium
Pedersen, 2016 [5]	1	0	0	1	2	0	1	1	Medium
Mithani, 2017 [4]	1	1	1	1	0	1	1	1	High
Honarbakhs, 2017 [9]	1	1	1	1	2	1	1	0	Medium
Köbe, 2017 [8]	1	1	0	1	1	0	1	0	High

Table A-2: Risk of bias – study level (observational studies) [11]*

* A study can be awarded a maximum of one point (= star) for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability

Table A-3:	Risk of bias –	- study level	(systematic a	review), see	[12]
------------	----------------	---------------	---------------	--------------	------

AMSTAR-2	Basu-Ray, 2017 [3]
Research question and inclusion criteria include the components of PICO	Yes
Explicit statement that the review methods were established prior to the conduct of the review	No
Explain their selection of the study designs for inclusion in the review	Yes
Comprehensive literature search strategy	Yes
Perform study selection in duplicate	Yes
Perform data extraction in duplicate	Yes
Provide a list of excluded studies and justify the exclusions	No
Describe the included studies in adequate detail	Yes
Satisfactory technique for assessing the risk of bias (RoB) in individual studies	Yes
Report on the sources of funding for the studies included in the review	No
Appropriate methods for statistical combination of results	Yes
Assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis	No
Account for RoB in individual studies when interpreting/discussing the results of the review	No
Satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review	No
Adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?	Yes
Report any potential sources of conflict of interest, including any funding they received for conducting the review?	Yes
Rating for overall confidence in the results of the review	Moderate*

Moderate – More than one non-critical weakness*: The systematic review has more than one weakness, but no critical flaws.

It may provide an accurate summary of the results of the available studies that were included in the review. [12].

Table A-4: Evidence profile: comparative effectiveness and safety of the subcutaneous and transvenous ICD in patients at increased risk for sudden cardiac death

Quality assessment					.№ of p	№ of patients		Effect				
.№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Subcutaneous ICD	Transvenous ICD	Relative (95% Cl)	Absolute (95% Cl)	Certainty	
Mortali	ty (In-hospital)	[10]	•									
1	observational studies	not serious	not serious	not serious	serious ^a	none	3/1920 (0.2%)	3/3840 (0.1%)	RR 2.0 (0.4 to 9.9)	1 more per 1.000 (from o fewer to 7 more)	⊕OOO VERY LOW	
Mortali	ty (up to 6 mor	1ths) [4]										
1	observational studies	serious b	not serious	not serious	serious ^{c,d}	none	2/91 (2.2%)	2/91 (2.2%)	RR 1.00 (0.14 to 6.95)	o fewer per 1.000 (from 19 fewer to 131 more)	⊕OOO VERY LOW	
Mortali	ty (up to 5 year	rs) [7]							•			
1	observational studies	not serious	not serious	not serious	serious ^{c,d}	none	2/140 (1.4%)	6/140 (4.3%)	-		⊕OOO VERY LOW	
Approp	riate shocks (7.	n months)	[6]						- <u>-</u>	•		
1	observational studies	serious ^b	not serious	not serious	serious ^{c,d}	none	3/69 (4.3%)	9/69 (13.0%)	RR 0.33 (0.09 to 1.18)	87 fewer per 1.000 (from 23 more to 119 fewer)	⊕OOO VERY LOW	
Approp	riate shocks (2.	6 years) [9	9]				·					
1	observational studies	not serious	not serious	not serious	serious ^{c,d}	none	3/69 (4.3%)	5/69 (7.2%)	RR 0.60 (0.15 to 2.14)	29 fewer per 1.000 (from 62 fewer to 83 more)	⊕OOO VERY LOW	
Approp	riate shocks (up	to 5 year	s) [7]						•			
1	observational studies	not serious	not serious	not serious	serious ^d	none	12/140 (8.6%)	24/140 (17.1%)	HR 0.68	51 fewer per 1.000 (from to)	⊕OOO VERY LOW	
Inappro	priate shocks [3] pooled	Data of [4, 6, 7,	9]			•					
4	observational studies	serious $^{\scriptscriptstyle b}$	not serious	not serious	serious ^a	none	29/369 (7.9%)	33/369 (8.9%)	OR 0.87 (0.51 to 1.49)	11 fewer per 1.000 (from 40 more to 44 fewer)	⊕OOO VERY LOW	
Lead co	mplications [3]	pooled Da	ata of [6, 7, 9, 10)]								
4	observational studies	serious ^e	not serious	not serious	not serious	none	3/2198 (0.1%)	42/4118 (1.0%)	OR 0.13 (0.05 to 0.38)	9 fewer per 1.000 (from 6 fewer to 10 fewer)	⊕OOO VERY LOW	
Infectio	ns [3] pooled D	ata of [4,	6, 7, 9, 10]									
5	observational studies	serious ^b	not serious	not serious	not serious	none	8/2289 (0.3%)	13/4209 (0.3%)	OR 0.75 (0.30 to 1.89)	1 fewer per 1.000 (from 2 fewer to 3 more)	⊕OOO VERY LOW	

Quality assessment					.№ of p	№ of patients		Effect			
.№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Subcutaneous ICD	Transvenous ICD	Relative (95% Cl)	Absolute (95% Cl)	Certainty
Pericard	Pericardial tamponade [9, 10]										
2	observational studies	not serious	not serious	not serious	serious ^c	none	0/1989 (0.0%)	6/3909 (0.2%)	RR ranged from 0.18 to 0.33	not estimable	⊕OOO VERY LOW
Haemat	:oma [4, 6, 10]										
3	observational studies	serious ^b	not serious	not serious	serious ^c	none	9/2080 (0.4%)	3/4000 (0.1%)	RR ranged from 3.0 to 3.5	not estimable	⊕OOO VERY LOW
Quality	of life – physic	al well-bei	ng score [8] (as	sessed with: 12	-item Short-Fe	orm Health Surve	y (SF-12))				
1	observational studies	serious ^b	not serious	not serious	serious ^d	none	42	42	-	MD 6.7 higher (1.88 higher to 11.52 higher)	⊕OOO VERY LOW
Quality	of life – physic	al well-bei	ng score [5] (as:	sessed with: 12	-item Short-Fo	orm Health Surve	y (SF-12))				
1	observational studies	not serious	not serious	not serious	serious ^d	none	167	167	-	MD 0.2 lower (2.67 lower to 2.27 higher)	⊕OOO VERY LOW
Quality	of life – menta	l well-bein	g score [8] (ass	essed with: 12-	item Short-Fo	rm Health Survey	/ (SF-12))				
1	observational studies	serious ^b	not serious	not serious	serious ^d	none	42	42	-	MD o.1 higher (4.43 lower to 4.63 higher)	⊕OOO VERY LOW
Quality	of life – menta	l well-bein	g score [5] (asse	essed with: 12-i	item Short-Fo	rm Health Survey	(SF-12))				
1	observational studies	not serious ^f	not serious	not serious	serious ^d	none	167	167	-	MD 0.15 higher (2.44 lower to 2.74 higher)	0000 VERY LOW

Abbreviations: CI = Confidence interval; RR = Risk ratio; HR = Hazard Ratio; OR = Odds ratio; MD = Mean difference

Explanations:

- ^a Effect estimates includes appreciable benefit and harms
- ^b Two studies with high risk of bias [4, 6]

^c Small number of events

- ^d Sample size does not meet optimal information size.
- ^e Studies with high or medium risk of bias

^f Medium risk of bias

Applicability table

Domain	Description of applicability of evidence
Population	Patients populations of included studies reflect real-world conditions with respect to age, sex, underlying cardiac condition and comorbidities.
Intervention	Included studies evaluated the subcutaneous ICD, produced by one manufacturer.
Comparators	Transvenous ICDs is considered as an established medical device, which is available from different manufacturers as single- or dual-chamber ICD.
Outcomes	Included studies reported several efficacy and safety outcomes, however, follow-up duration considerably differs among studies. Thus, long-term complications are only reflected by one study.
Setting	Studies were conducted in real-world settings.

Table A-5: Summary table characterising the applicability of a body of studies

List of ongoing randomised controlled trials

Table A-6: List of ongoing randomised controlled trials of subcutaneous ICD

Identifier/ Trial name	Patient population	Intervention	Comparison	Primary Outcome	Primary completion date	Sponsor and Collaborator:
NCT01296022 PRAETORIAN	Patients 18 years and older with class I or IIa indication for ICD therapy according to the ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Estimated enrollment: 850 patients	Subcutaneous ICD	Transvenous ICD	Number of participants with implantable cardioverter defibrillator (ICD) related adverse events (48 months)	Estimated: December 2019	Academisch Medisch Centrum-Universiteit van Amsterdam (AMC-UvA) Boston Scientific Corporation
NCT02881255 ATLAS S-ICD	Patient is ≥ 18-60 years old AND has a standard indication for ICD; OR Patient is ≥ 18 years old AND has any one of the following present: An inherited arrhythmia syndrome (i.e. Long QT, Brugada, ARVC, hypertrophic or dilated cardiomyopathy, early repolarization syndrome, idiopathic ventricular fibrillation, etc.), prior pacemaker or ICD removal for infection, need for hemodialysis, prior heart valve surgery (repair or replacement), Chronic obstructive pulmonary disease (with FEV1 < 1.5 L) Estimated enrollment: 500 patients	Subcutaneous ICD (Boston Scientific EMBLEM™)	Single- chamber, transvenous ICD	Composite of lead-related perioperative complications (6 months) Additional safety composite (6 months)	Estimated: August 2018	Population Health Research Institute Boston Scientific Corporation

Abbreviations: ATALS = Avoid Transvenous Leads in Appropriate Subjects, PRAETORIAN = Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy, ICD = Impantable cardioverter defibrillator

Literature search strategies

Search strategy for Pubmed

Search Name: Subcutaneous ICD					
Search Date: November 23 rd , 2017					
ID	Search				
#1	Search S-ICD[tw]				
#2	Search subcutaneous*[tw]				
#3	Search "Defibrillators, Implantable"[Mesh]				
#4	Search cardioverter*[tiab]				
#5	Search defibrillator*[tiab]				
#6	Search ICD[tiab]				
#7	Search (#3 OR #4 OR #5 OR #6)				
#8	Search (#2 AND #7)				
#9	Search (#1 OR #8)				
#10	Search "Animals"[Mesh] NOT "Humans"[Mesh]				
#11	1 Search #9 NOT #10				
#12	Search (#11) AND ("2000"[Date - Publication] : "3000"[Date - Publication])				
#13	Search "Case Reports" [Publication Type] OR (case*[ti] AND (report*[ti] OR series[ti]))				
#14	Search (#12 NOT #13)				
Total:	410 Hits				

Search strategy for Embase.com (Elsevier)

Search	Search Name: Subcutaneous ICD					
Search Date: November 23 rd , 2017						
ID	Search					
#1	's icd':ti,ab					
#2	(subcutaneous* NEAR/4 (defibrillator* OR cardioverter* OR icd)):ti,ab					
#3	'implantable cardioverter defibrillator'/exp AND subcutaneous*					
#4	#1 OR #2 OR #3					
#5	'animal'/exp NOT 'human'/exp					
#6	#4 NOT #5					
#7	7 #6 AND [2000-2017]/py					
#8	'case study'/exp OR 'case report'/exp OR ((case* NEAR/3 (report OR series)):ti)					
#9	#7 NOT #8					
#10	#9 NOT 'conference abstract'/it					
Total: 341 Hits						

Search strategy for Cochrane Library (Wiley)

Search Name: Subcutaneous ICD						
Search Date: November 23 rd , 2017						
ID	Search					
#1	S-ICD:ti,ab,kw					
#2	subcutaneous* near/4 (defibrillator* or Cardioverter* or ICD)					
#3	subcutaneous*:ti,ab,kw					
#4	[mh "Defibrillators, Implantable"]					
#5	cardioverter*:ti,ab,kw					
#6	defibrillator*:ti,ab,kw					
#7	ICD:ti,ab,kw					
#8	{or, #4-`#7}					
#9	#3 and #8					
#10	#1 Or #2 Or #9					
#11	#10 Publication Year from 2000 to 2017					
Total: 79 Hits						

Search strategy for CRD Databases

Search	Search Name: Subcutaneous ICD				
Search Date: November 23 rd , 2017					
ID	ID Search				
#1	MeSH DESCRIPTOR Defibrillators, Implantable EXPLODE ALL TREES				
#2	(Subcutaneous*)				
#3	#1 AND #2				
#4	. (S-ICD)				
#5	#5 (subcutaneous* NEAR4 (defibrillator* OR Cardioverter* OR ICD))				
#6	#6 #3 OR #4 OR #5				
Total:	Total: 5 Hits				

